0001564590-21-042177 | 10-Q | XBRL Viewer | Allscripts Healthcare Solutions INC

June 30, 2021

Asset Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and other current assets

Total derivatives

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Aug. 02, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	0001124804
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		125,010,868
Entity File Number	001-35547
Entity Tax Identification Number	36-4392754
Entity Address, Address Line One	222 Merchandise Mart
Entity Address, Address Line Two	Suite 2024
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	800
Local Phone Number	334-8534
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 229,254	$ 531,104
Restricted cash	2,129	6,361
Accounts receivable, net of allowance of $31,991 and $31,596 as of June 30, 2021 and December 31, 2020, respectively	338,587	347,355
Contract assets, net of allowance of $1,068 as of June 30, 2021 and December 31, 2020	120,051	106,717
Income tax receivable	0	25,421
Prepaid expenses and other current assets	150,968	136,264
Total current assets	840,989	1,153,222
Fixed assets, net	59,077	72,162
Software development costs, net	182,848	193,202
Intangible assets, net	261,258	286,602
Goodwill	974,834	974,729
Deferred taxes, net	5,872	5,790
Contract assets - long-term, net of allowance of $4,273 as of June 30, 2021 and December 31, 2020	49,849	43,682
Right-of-use assets - operating leases	75,052	96,601
Other assets	90,521	91,628
Total assets	2,540,300	2,917,618
Current liabilities:
Accounts payable	26,782	35,905
Accrued expenses	88,780	100,262
Accrued compensation and benefits	94,185	118,771
Deferred revenue	364,000	334,764
Current operating lease liabilities	19,662	22,264
Current liabilities attributable to discontinued operations	2,670	322,811
Total current liabilities	596,079	934,777
Long-term debt	421,312	167,587
Deferred revenue	2,862	3,471
Deferred taxes, net	17,797	18,186
Long-term operating lease liabilities	71,597	93,463
Other liabilities	37,179	33,891
Total liabilities	1,146,826	1,251,375
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of June 30, 2021 and December 31, 2020	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of June 30, 2021 and December 31, 2020; 276,668 and 125,011 shares issued and outstanding as of June 30, 2021, respectively; 274,558 and 139,942 shares issued and outstanding as of December 31, 2020, respectively	2,766	2,745
Treasury stock: at cost, 151,657 and 134,616 shares as of June 30, 2021 and December 31, 2020, respectively	(1,174,498)	(870,558)
Additional paid-in capital	1,903,542	1,902,776
Retained earnings	664,101	633,118
Accumulated other comprehensive loss	(2,437)	(1,838)
Total stockholders’ equity	1,393,474	1,666,243
Total liabilities and stockholders’ equity	$ 2,540,300	$ 2,917,618

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 31,991	$ 31,596
Contract assets, allowance	1,068	1,068
Contract assets - long-term, allowance	$ 4,273	$ 4,273
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	276,668,000	274,558,000
Common stock, shares outstanding	125,011,000	139,942,000
Treasury stock at cost, shares	151,657,000	134,616,000

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Revenue from contract with customers	$ 373,714	$ 369,304	$ 742,066	$ 750,668
Cost of revenue:
Amortization of software development and acquisition-related assets	30,061	29,405	59,550	57,529
Total cost of revenue	221,961	231,706	440,268	481,134
Gross profit	151,753	137,598	301,798	269,534
Selling, general and administrative expenses	79,090	109,897	160,798	202,722
Research and development	51,219	46,045	100,392	105,422
Asset impairment charges	5,244	0	5,244	0
Amortization of intangible and acquisition-related assets	5,825	6,321	11,649	13,031
Income (loss) from operations	10,375	(24,665)	23,715	(51,641)
Interest expense	(2,949)	(10,314)	(6,092)	(20,979)
Other income (loss), net	16,757	(875)	17,794	(353)
Impairment of long-term investments	0	(550)	0	(550)
Equity in net (loss) income of unconsolidated investments	(86)	16,834	(64)	17,034
Income (loss) from continuing operations before income taxes	24,097	(19,570)	35,353	(56,489)
Income tax (provision) benefit	(2,192)	(2,009)	(4,855)	2,525
Income (loss) from continuing operations, net of tax	21,905	(21,579)	30,498	(53,964)
Income from discontinued operations	36	18,838	7	35,056
Gain on sale of discontinued operations	0	0	647	0
Income tax effect on discontinued operations	(15)	(4,864)	(169)	(9,051)
Income from discontinued operations, net of tax	21	13,974	485	26,005
Net income (loss)	$ 21,926	$ (7,605)	$ 30,983	$ (27,959)
Basic
Continuing operations	$ 0.16	$ (0.13)	$ 0.22	$ (0.33)
Discontinued operations	0.00	0.08	0.00	0.16
Net income (loss) per share - Basic	0.16	(0.05)	0.22	(0.17)
Diluted
Continuing operations	0.15	(0.13)	0.21	(0.33)
Discontinued operations	0.00	0.08	0.00	0.16
Net income (loss) per share - Diluted	$ 0.15	$ (0.05)	$ 0.21	$ (0.17)
Software delivery, Support and Maintenance [Member]
Revenue:
Revenue from contract with customers	$ 219,610	$ 223,591	$ 442,301	$ 455,731
Cost of revenue:
Total cost of revenue	69,303	71,130	140,034	144,214
Client services [Member]
Revenue:
Revenue from contract with customers	154,104	145,713	299,765	294,937
Cost of revenue:
Total cost of revenue	$ 122,597	$ 131,171	$ 240,684	$ 279,391

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 21,926	$ (7,605)	$ 30,983	$ (27,959)
Other comprehensive income (loss):
Foreign currency translation adjustments	421	918	520	(1,594)
Change in fair value of derivatives qualifying as cash flow hedges	(828)	1,084	(1,509)	611
Other comprehensive income (loss) before income tax benefit	(407)	2,002	(989)	(983)
Income tax benefit related to items in other comprehensive income (loss)	214	(280)	390	(158)
Total other comprehensive income (loss)	(193)	1,722	(599)	(1,141)
Comprehensive income (loss)	$ 21,733	$ (5,883)	$ 30,384	$ (29,100)

- Definition

Amount before tax, after reclassification adjustments of other comprehensive income (loss).

+ References + Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Amount of tax expense (benefit) allocated to other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]	Retained Earnings (Accumulated Deficit) [Member] Cumulative Effect Period Of Adoption Adjustment [Member] Revision Of Prior Period Accounting Standards Update Adjustment [Member]	Accumulated Other Comprehensive Loss [Member]	Noncontrolling Interest
Beginning Balance, Shares at Dec. 31, 2019		272,609,000	(110,134,000)
Beginning Balance at Dec. 31, 2019	$ 1,285,188	$ 2,725	$ (571,157)	$ 1,907,348	$ (49,336)	$ (17,953)	$ (4,392)
Stock-based compensation				17,120
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,854,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 18		(5,544)
Capped call transactions				797
Issuance of treasury stock, Shares			90,000
Issuance of treasury stock	752		$ 1,193	(440)
Purchase of treasury stock, Shares			(1,449,000)
Purchase of treasury stock			$ (9,714)
Accelerated share repurchase program, Shares			0
Accelerated share repurchase program			$ 0	0
Warrants issued				1,364
Net income (loss)	(27,959)
Foreign currency translation adjustments, net	(1,594)						(1,594)
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges, net of tax							453
Ending Balance, Shares at Jun. 30, 2020		274,463,000	(111,493,000)
Ending Balance at Jun. 30, 2020	1,242,929	$ 2,743	$ (579,678)	1,920,645	(95,248)			$ (5,533)
Beginning Balance, Shares at Dec. 31, 2019		272,609,000	(110,134,000)
Beginning Balance at Dec. 31, 2019	$ 1,285,188	$ 2,725	$ (571,157)	1,907,348	(49,336)	(17,953)	(4,392)
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	1,900,000
Ending Balance, Shares at Dec. 31, 2020	274,558,000	274,558,000	(134,616,000)
Ending Balance at Dec. 31, 2020	$ 1,666,243	$ 2,745	$ (870,558)	1,902,776	633,118	0	(1,838)
Beginning Balance, Shares at Mar. 31, 2020		273,484,000	(111,583,000)
Beginning Balance at Mar. 31, 2020	$ 1,241,780	$ 2,733	$ (580,871)	1,914,816	(87,643)	0	(7,255)
Stock-based compensation				7,166
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		979,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 10		(2,376)
Capped call transactions				797
Issuance of treasury stock, Shares			90,000
Issuance of treasury stock			$ 1,193	(440)
Purchase of treasury stock, Shares	0		0
Purchase of treasury stock			$ 0
Accelerated share repurchase program, Shares			0
Accelerated share repurchase program			$ 0	0
Warrants issued				682
Net income (loss)	$ (7,605)
Foreign currency translation adjustments, net	918						918
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges, net of tax							804
Ending Balance, Shares at Jun. 30, 2020		274,463,000	(111,493,000)
Ending Balance at Jun. 30, 2020	$ 1,242,929	$ 2,743	$ (579,678)	1,920,645	(95,248)			(5,533)
Beginning Balance, Shares at Dec. 31, 2020	274,558,000	274,558,000	(134,616,000)
Beginning Balance at Dec. 31, 2020	$ 1,666,243	$ 2,745	$ (870,558)	1,902,776	633,118	0	(1,838)
Stock-based compensation				17,084
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	2,100,000	2,110,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 21		(13,912)
Capped call transactions				0
Issuance of treasury stock, Shares			33,000
Issuance of treasury stock	$ 534		$ 465	69
Purchase of treasury stock, Shares			(6,397,000)
Purchase of treasury stock			$ (108,953)
Accelerated share repurchase program, Shares			(10,677,000)
Accelerated share repurchase program			$ (195,452)	(4,548)
Warrants issued				2,073
Net income (loss)	$ 30,983
Accounting Standards Update Extensible List	Accounting Standards Update 2016-13 [Member]
Foreign currency translation adjustments, net	$ 520						520
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges, net of tax							(1,119)
Ending Balance, Shares at Jun. 30, 2021	276,668,000	276,668,000	(151,657,000)
Ending Balance at Jun. 30, 2021	$ 1,393,474	$ 2,766	$ (1,174,498)	1,903,542	664,101			(2,437)
Beginning Balance, Shares at Mar. 31, 2021		275,241,000	(134,616,000)
Beginning Balance at Mar. 31, 2021	1,678,658	$ 2,751	$ (870,558)	1,906,534	642,175	$ 0	(2,244)
Stock-based compensation				8,383
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,427,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 15		(7,932)
Capped call transactions				0
Issuance of treasury stock, Shares			33,000
Issuance of treasury stock			$ 465	69
Purchase of treasury stock, Shares			(6,397,000)
Purchase of treasury stock			$ (108,953)
Accelerated share repurchase program, Shares			(10,677,000)
Accelerated share repurchase program			$ (195,452)	(4,548)
Warrants issued				1,036
Net income (loss)	21,926
Foreign currency translation adjustments, net	$ 421						421
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges, net of tax							$ (614)
Ending Balance, Shares at Jun. 30, 2021	276,668,000	276,668,000	(151,657,000)
Ending Balance at Jun. 30, 2021	$ 1,393,474	$ 2,766	$ (1,174,498)	$ 1,903,542	$ 664,101			$ (2,437)

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net income (loss)	$ 30,983	$ (27,959)
Less: Income from discontinued operations	485	26,005
Income (loss) from continuing operations	30,498	(53,964)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization	88,713	99,305
Non-cash lease expense, net	(2,527)	219
Stock-based compensation expense	17,084	17,120
Deferred taxes	(100)	3,132
Asset impairment charges	5,244	0
Impairment of long-term investments	0	550
Equity in net loss (income) of unconsolidated investments	64	(17,034)
Other income, net	(7,617)	(2,696)
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net	34,175	46,795
Prepaid expenses and other assets	(12,317)	(15,069)
Accounts payable	(8,802)	(27,064)
Accrued expenses	18,393	1,987
Accrued compensation and benefits	(24,613)	13,889
Deferred revenue	(16,328)	(15,496)
Other liabilities	3,288	1,615
Accrued DOJ settlement	0	(73,020)
Net cash provided by (used in) operating activities - continuing operations	125,155	(19,731)
Net cash (used in) provided by operating activities - discontinued operations	(321,517)	38,669
Net cash (used in) provided by operating activities	(196,362)	18,938
Cash flows from investing activities:
Capital expenditures	(3,094)	(4,778)
Capitalized software	(35,472)	(50,912)
Cash received from sale of businesses, net of cash divested	952	0
Purchases of equity securities, other investments and related intangible assets, net	(221)	(3,823)
Sale of other investments	1,919	23,254
Distributions received from investments	1,371	0
Net cash used in investing activities - continuing operations	(34,545)	(36,259)
Net cash used in investing activities - discontinued operations	0	(4,447)
Net cash used in investing activities	(34,545)	(40,706)
Cash flows from financing activities:
Taxes paid related to net share settlement of equity awards	(13,887)	(5,533)
Payments for issuance costs on 0.875% Convertible Senior Notes	0	(758)
Repayment of Convertible Senior Notes	0	(7,361)
Credit facility payments	0	(167,500)
Credit facility borrowings, net of issuance costs	250,000	285,000
Repurchase of common stock	(108,953)	(9,714)
Payment of acquisition and other financing obligations	(2,400)	(4,369)
Net cash (used in) provided by financing activities	(75,240)	89,765
Effect of exchange rate changes on cash and cash equivalents	65	(338)
Net (decrease) increase in cash and cash equivalents	(306,082)	67,659
Cash, cash equivalents and restricted cash, beginning of period	537,465	137,539
Cash, cash equivalents and restricted cash, end of period	231,383	205,198
Accelerated Share Repurchase Program [Member]
Cash flows from financing activities:
Repurchase of common stock	$ (200,000)	$ 0

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (Unaudited)	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019
0.875% Convertible Senior Notes [Member]
Debt instrument interest rate	0.875%	0.875%	0.875%

Basis of Presentation and Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

1. Basis of Presentation and Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.

Unaudited Interim Financial Information

The unaudited interim consolidated financial statements as of and for the three and six months ended June 30, 2021 and 2020 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021.

Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (our “Form 10-K”).

Use of Estimates

The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates.

Change in Presentation

Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported consolidated prior period financial results.

Significant Accounting Policies

There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.

Recently Adopted Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2019-12, “Income Taxes (Topic 740)” (“ASU 2019-12”), which is part of the FASB’s overall simplification initiative to reduce the costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. ASU 2019-12 simplifies accounting guidance for intraperiod allocations, deferred tax liabilities, year-to-date losses in interim periods, franchise taxes, step-up in tax basis of goodwill, separate entity financial statements and interim recognition of tax laws or rate changes. ASU 2019-12 is effective for public business entities for annual reporting periods beginning after December 15, 2020. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have a significant impact on our consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

In August 2020, the FASB issued Accounting Standards Update No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The amendments in ASU 2020-06 simplify the accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. We are currently evaluating the impact of this accounting guidance.

We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.

Revenue from Contracts with Customers

6 Months Ended

Jun. 30, 2021

Revenue From Contract With Customer [Abstract]

Revenue from Contracts with Customers

2. Revenue from Contracts with Customers

Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery, support and maintenance revenue consists of all of our proprietary software sales (either under a perpetual or term license delivery model), subscription-based software sales, transaction-related revenue, the resale of hardware and third-party software and revenue from post-contract client support and maintenance services, which include telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services and project-based revenue from implementation, training and consulting services. For some clients, we host the software applications licensed from us using our own or third-party servers. For other clients, we offer an outsourced service in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees.

At June 30, 2021 and December 31, 2020, we had capitalized costs to obtain or fulfill a contract of $15.5 million and $16.8 million, respectively, in Prepaid and other current assets and $27.2 million and $27.9 million, respectively, in Other assets. During the three months ended June 30, 2021 and 2020, we recognized $4.9 million and $5.8 million, respectively, of amortization expense related to such capitalized costs. During the six months ended June 30, 2021 and 2020, we recognized $10.7 million and $12.5 million, respectively, of amortization expense related to such capitalized costs. The amortization of these capitalized costs to obtain a contract are included in Selling, general and administrative expense within our consolidated statements of operations.

The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivable, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue.

The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the table below:

(In thousands)	Three Months Ended March 31, 2021		Three Months Ended June 30, 2021
Revenue related to deferred revenue balance at beginning of period	$	137,848	$	151,857
Revenue related to new performance obligations satisfied during the period		173,316		158,910
Revenue recognized under "right-to-invoice" expedient		56,811		62,422
Reimbursed travel expenses, shipping and other revenue		377		525
Total revenue	$	368,352	$	373,714

(In thousands)	Three Months Ended March 31, 2020		Three Months Ended June 30, 2020
Revenue related to deferred revenue balance at beginning of period	$	105,366	$	119,545
Revenue related to new performance obligations satisfied during the period		216,580		195,308
Revenue recognized under "right-to-invoice" expedient		58,059		54,082
Reimbursed travel expenses, shipping and other revenue		1,359		369
Total revenue	$	381,364	$	369,304

The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations (commonly referred to as “backlog”) represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total backlog equaled $3.9 billion as of June 30, 2021, of which we expect to recognize approximately 33% over the next 12 months, and the remaining 67% thereafter.

Revenue Recognition

We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer.

The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Revenue:
Recurring revenue	$	303,644	$	303,196	$	599,292	$	613,177
Non-recurring revenue		70,070		66,108		142,774		137,491
Total revenue	$	373,714	$	369,304	$	742,066	$	750,668

	Three Months Ended June 30, 2021
(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Unallocated Amounts			Total
Software delivery, support and maintenance	$	158,754	$	65,150	$	(4,294	)	$	219,610
Client services		151,394		2,710		0			154,104
Total revenue	$	310,148	$	67,860	$	(4,294	)	$	373,714

	Three Months Ended June 30, 2020
(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Unallocated Amounts			Total
Software delivery, support and maintenance	$	167,220	$	58,664	$	(2,293	)	$	223,591
Client services		143,879		1,834		0			145,713
Total revenue	$	311,099	$	60,498	$	(2,293	)	$	369,304

	Six Months Ended June 30, 2021
(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Unallocated Amounts			Total
Software delivery, support and maintenance	$	323,964	$	127,009	$	(8,672	)	$	442,301
Client services		295,349		4,416		0			299,765
Total revenue	$	619,313	$	131,425	$	(8,672	)	$	742,066

	Six Months Ended June 30, 2020
(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Unallocated Amounts			Total
Software delivery, support and maintenance	$	341,301	$	119,122	$	(4,692	)	$	455,731
Client services		290,130		4,807		0			294,937
Total revenue	$	631,431	$	123,929	$	(4,692	)	$	750,668

Contract Assets – Estimate of Credit Losses

We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. The guidance required the recognition of lifetime estimated credit losses expected to occur for contract assets and trade receivables. The guidance also required that we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of ASU 2016-13 for contract assets was recorded as a debit to retained earnings of $5.3 million as of January 1, 2020. Refer to Note 3, “Accounts Receivable”, for the adoption impact related to trade receivables.

At adoption, we segmented the contract asset population into pools based on their risk assessment. Risks related to contract assets are a customer’s inability to pay or bankruptcy. Each pool was defined by an internal credit assessment and business size. The pools were aligned with management’s review of financial performance at the time. In the fourth quarter of 2020, we used each customer’s primary business unit in our pooling determination. This assessment provides additional information of the customer including size, segment and industry. Using this perspective, we added one new pool. We reallocated pools and loss rates accordingly and noted slight shifts in each pool. The new pools are aligned with management’s current review of financial performance. For the six months ended June 30, 2021, no adjustment to the pools was necessary.

We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a twenty-four-month lookback period of credit memos and adjustments divided by the average contract asset balance for each pool during that period. We considered current economic conditions, including how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. The June 30, 2021 analysis resulted in no change in the ending estimate of credit losses.

Changes in the estimate of credit losses for contract assets are presented in the table below.

(In thousands)	Total
Balance at December 31, 2020	$	5,341
Current period provision		0
Balance at June 30, 2021	$	5,341
Less: Contract assets, short-term		1,068
Total contract assets, long-term	$	4,273

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Accounts Receivables

6 Months Ended

Jun. 30, 2021

Receivables [Abstract]

Accounts Receivables

3. Accounts Receivable

Trade Accounts Receivable – Estimate of Credit Losses

We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. The guidance required the recognition of lifetime estimated credit losses expected to occur for trade accounts receivable, which resulted in the recording of a debit to retained earnings of $12.6 million as of January 1, 2020. Refer to Note 2, “Revenue from Contracts with Customers” for additional information regarding the adoption of ASU 2016-13.

Changes in the estimate of credit losses for trade accounts receivable are presented in the tables below.

(In thousands)	Total
Balance at December 31, 2020	$	31,596
Current period provision		1,655
Write-offs		(1,721	)
Recoveries		461
Balance at June 30, 2021	$	31,991

Leases

6 Months Ended

Jun. 30, 2021

Lessee Disclosure [Abstract]

Leases

4. Leases

We determine whether an arrangement is a lease at inception. Assets leased under an operating lease arrangement are recorded in Right-of-use assets – operating leases and the associated lease liabilities are included in Current operating lease liabilities and Long-term operating lease liabilities within the consolidated balance sheets. Assets leased under finance lease arrangements are recorded within fixed assets and the associated lease liabilities are recorded within Accrued expenses and Other liabilities within the consolidated balance sheets.

Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate in conjunction with the market swap rate for the expected remaining lease term at the commencement date for new leases in determining the present value of future lease payments. Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

We have elected the group of practical expedients under ASU 2016-02 to forego assessing upon adoption: (1) whether any expired contracts are or contain leases; (2) the lease classification for any existing or expired leases and (3) any indirect costs that would have qualified for capitalization for any existing leases. We have lease agreements with lease and non-lease components, which are generally accounted for separately except for real estate and vehicle leases, which we have elected to combine through a practical expedient under ASU 2016-02. Non-lease components for our leases typically consist of executory costs, and the practical expedient allows for executory costs to be recorded as lease payments. Additionally, for certain equipment leases, we apply a portfolio approach to effectively record right-of-use assets and liabilities.

Our operating leases mainly include office leases and our finance leases include office and computer equipment leases. Our finance leases are not significant. Our leases have remaining lease terms up to 7 years, some of which include options to extend the leases for up to 5 years, which may include options to terminate the leases within 1 year. Operating costs associated with leased assets are as follows:

(In thousands)	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Operating lease cost ⁽¹⁾	$	5,636		$	6,261		$	11,697		$	13,014
Less: Sublease income		(74	)		(166	)		(157	)		(769	)
Total operating lease costs	$	5,562		$	6,095		$	11,540		$	12,245

(1)	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations.

Supplemental cash flow information for operating leases is as follows:

(In thousands)	Six Months Ended June 30,
	2021		2020
Operating cash flows from operating leases	$	10,083	$	13,953
Right-of-use assets obtained in exchange for operating lease obligations	$	0	$	21,963

The balance sheet location and balances for operating leases are as follows:

(In thousands, except lease term and discount rate)	June 30, 2021			December 31, 2020
Right-of-use assets - operating leases	$	75,052		$	96,601
Current operating lease liabilities	$	19,662		$	22,264
Long-term operating lease liabilities	$	71,597		$	93,463
Weighted average remaining lease term (in years)		5			6
Weighted average discount rate		3.3	%		3.6	%

The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of June 30, 2021.

	June 30, 2021
(In thousands)	Operating Leases
Remainder of 2021	$	11,590
2022		21,348
2023		19,547
2024		14,114
2025		12,764
Thereafter		20,104
Total lease liabilities		99,467
Less: Amount representing interest		(8,208	)
Less: Short-term lease liabilities		(19,662	)
Total long-term lease liabilities	$	71,597

Business Combinations and Divestitures

6 Months Ended

Jun. 30, 2021

Business Combinations [Abstract]

Business Combinations and Divestitures

5. Business Combinations and Divestitures

Acquisitions

On July 2, 2019, we acquired the Pinnacle and Diabetes Collaborative Registries from the American College of Cardiology (“ACC”) as part of our broader strategic partnership with the ACC. The total purchase price was $19.7 million, consisting of an initial payment of $11.7 million plus up to an aggregate of $8.0 million pending the attainment of certain milestones over the next 18 months. The contingent consideration of up to $8.0 million was valued at $5.0 million at the time of closing. As part of this partnership, we operate Pinnacle and Diabetes Collaborative Registries, which extends our EHR-enabled ambulatory network to create a large-scale chronic disease network. During the first quarter of 2021, we extended the ACC earnout agreement to June 30, 2021. In the second quarter of 2021, we paid $0.9 million related to the earnout agreement. The remaining payment was accrued as contingent consideration within our consolidated financial statements. Refer to Note 6, “Fair Value Measurements and Long-term Investments” for additional information regarding the contingent consideration. The business is included in our Data, Analytics and Care Coordination business segment.

Divestitures

On December 31, 2020, we completed the sale of substantially all of the assets of our CarePort business to a subsidiary of WellSky Corp., a Delaware corporation (“WellSky”), pursuant to a purchase agreement (the “CarePort Purchase Agreement”). The total consideration for CarePort was $1.35 billion, which was subject to certain adjustments for liabilities assumed by WellSky and net working capital as described in the CarePort Purchase Agreement. We realized a pre-tax gain upon the sale of $933.9 million, which was included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2020. For the six months ended June 30, 2021, we recorded a $0.6 million gain that primarily related to net working capital adjustments in the Gain on sale of discontinued operations line in our consolidated statements of operations. The divestiture was treated as a discontinued operation as of December 31, 2020. Refer to Note 15, “Discontinued Operations” for additional information. On December 31, 2020, we repaid $161.0 million of the Term Loan (as defined below) as a result of the sale, which was a mandatory prepayment in accordance with the Second Amended Credit Agreement (as defined below).

On October 15, 2020, we completed the sale of substantially all of the assets of our EPSi^TM business (“EPSi”) to Strata Decision Technology LLC, an Illinois limited liability company (“Strata”), and Roper Technologies, Inc., a Delaware corporation, pursuant to a purchase agreement (the “EPSi Purchase Agreement”). The total consideration for EPSi was $365.0 million, which was subject to certain adjustments for liabilities assumed by Strata and net working capital as described in the EPSi Purchase Agreement. We realized a pre-tax gain upon the sale of $222.6 million, which was included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2020. The divestiture was treated as a discontinued operation as of December 31, 2020. Refer to Note 15, “Discontinued Operations” for additional information. On October 29, 2020, we repaid $19.0 million of the Term Loan (as defined below) as a result of the sale, which was a mandatory prepayment in accordance with the Second Amended Credit Agreement (as defined below).

Fair Value Measurements and Long-term Investments

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements and Long-term Investments

6. Fair Value Measurements and Long-term Investments

Fair value measurements are based upon observable and unobservable inputs.

Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates.

Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instrument includes the fair value of contingent consideration related to a completed acquisition. The fair value is based on a discounted cash flow analysis reflecting the likelihood of achieving specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, or time value of money.

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:

	Balance Sheet	June 30, 2021								December 31, 2020
(In thousands)	Classifications	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Foreign exchange derivative assets	Prepaid expenses and other current assets	$	0	$	0	$	0	$	0	$	0	$	1,509	$	0	$	1,509
Total assets		$	0	$	0	$	0	$	0	$	0	$	1,509	$	0	$	1,509

Contingent consideration - current	Accrued expenses	$	0	$	0	$	153	$	153	$	0	$	0	$	1,011	$	1,011
Total liabilities		$	0	$	0	$	153	$	153	$	0	$	0	$	1,011	$	1,011

The changes in our Level 3 liability measured at fair value on a recurring basis at June 30, 2021 is summarized as follows:

(In thousands)	Contingent Consideration
Balance at December 31, 2020	$	1,011
Payments		(858	)
Balance at June 30, 2021	$	153

The following table summarizes the quantitative information about our Level 3 fair value measurements at June 30, 2021:

June 30, 2021

(In thousands, except the discount rate)

Fair Value

Valuation Technique

Significant Unobservable Inputs

Ranges of Inputs

Weighted Average ⁽¹⁾

Financial instruments:

Contingent consideration

153

Probability Weighted Discounted cash flow

Discount rate

5.3% to 5.5%

5.4

Registry members

0 to 1,551

776

Patient data volume

0 to 52,845

26,422

Projected year of payment

2021

Total financial instruments

153

(1)	The weighted average is calculated based upon the absolute fair value of the instruments.

Long-term Investments

The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets:

	Number of Investees		Original		Carrying Value at
(In thousands, except for number of investees)	at June 30, 2021		Cost		June 30, 2021		December 31, 2020
Equity method investments ⁽¹⁾		3	$	7,099	$	10,438	$	10,744
Cost less impairment		8		37,568		37,976		25,059
Total long-term equity investments		11	$	44,667	$	48,414	$	35,803

(1)	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

During the three and six months ended June 30, 2021, one of our third-party cost method investments converted its notes and we received 475 thousand shares as a result of the conversion. We also revalued our existing investment based on the note conversion share price. The note conversion and the revaluation of the existing investment resulted in a $9.7 million gain, which is included in the Other income (loss), net line in our consolidated statements of operations for the three and six months ended June 30, 2021.

During the six months ended June 30, 2020, we recorded a $16.8 million gain from the sale of a third-party equity method investment.

As of June 30, 2021, it is not possible to estimate the fair value of our non-marketable cost and equity method investments, primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations, the issuer’s subsequent or planned raises of capital and observable price changes in orderly transactions.

Impairment of Long-term Investments

Each quarter, management performs an assessment of each of our investments on an individual basis to determine if there have been any declines in fair value. Based on our assessment, we determined no impairment charges were necessary for the six months ended June 30, 2021.

Long-term Financial Liabilities

Our long-term financial liabilities include amounts outstanding under our senior secured credit facility (as described in Note 10, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. Refer to Note 10, “Debt,” for further information regarding our long-term financial liabilities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Stockholders' Equity

7. Stockholders' Equity

Stock-based Compensation Expense

Stock-based compensation expense recognized during the three and six months ended June 30, 2021 and 2020 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three and six months ended June 30, 2021 and 2020.

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Cost of revenue:
Software delivery, support and maintenance	$	311	$	343	$	807	$	918
Client services		967		808		2,346		1,899
Total cost of revenue		1,278		1,151		3,153		2,817
Selling, general and administrative expenses		7,551		5,081		15,594		12,123
Research and development		1,554		1,428		3,467		3,823
Total stock-based compensation expense	$	10,383	$	7,660	$	22,214	$	18,763

Allscripts Long-Term Incentive Plan

We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved.

The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three and six months ended June 30, 2021 and 2020.

We granted stock-based awards as follows:

	Three Months Ended June 30, 2021				Six Months Ended June 30, 2021
			Weighted-Average				Weighted-Average
			Grant Date				Grant Date
(In thousands, except per share amounts)	Shares		Fair Value		Shares		Fair Value
Service-based restricted stock units		1,963	$	15.41		2,445	$	15.36
Performance-based restricted stock units with a service condition		0	$	0.00		235	$	15.16
Market-based restricted stock units with a service condition		0	$	0.00		235	$	17.19
		1,963	$	15.41		2,915	$	15.49

During the six months ended June 30, 2021 and the year ended December 31, 2020, 2.1 million and 1.9 million shares of common stock, respectively, were issued in connection with the release of restrictions on stock awards.

Net Share-settlements

Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax, and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the six months ended June 30, 2021 and 2020 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the six months ended June 30, 2021 and 2020 were 895 thousand and 764 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting.

Stock Repurchases

On November 18, 2020, we announced that our Board approved a stock purchase program (the “2020 Program”) under which we may repurchase up to $300 million of our common stock through December 31, 2021. The 2020 Program replaced a previous program. During the three and six months ended June 30, 2021, we repurchased 5.6 million shares of our common stock under the 2020 Program. This is inclusive of the shares we received at final settlement of the accelerated share repurchase program we entered into on November 30, 2020, described below. During the six months ended June 30, 2020, we repurchased 1.5 million shares of our common stock under the previous program for a total of $9.7 million. We repurchased no shares during the three months ended June 30, 2020.

On May 26, 2021, we announced that our Board approved a new stock purchase program (the “2021 Program”) under which we may repurchase up to $350 million of our common stock. The 2021 Program replaced the 2020 Program and does not have a termination date. During the three months ended June 30, 2021, we repurchased 11.5 million shares of our common stock under the 2021 Program. This is inclusive of the shares we received at initial settlement of the accelerated share repurchase program entered into on June 14, 2021, described below.

On November 30, 2020, we entered into separate Master Confirmations (each, a “Master Confirmation”) and Supplemental Confirmations (each, together with the related Master Confirmation, an “ASR Agreement”), with JPMorgan Chase Bank, National Association and Wells Fargo Bank, National Association (each, an “ASR Counterparty”, or collectively, “ASR Counterparties”), to purchase shares of our common stock for a total payment of $200.0 million (the “Prepayment Amount”). Under the terms of the ASR Agreements, on November 30, 2020, we paid the Prepayment Amount to the ASR Counterparties and received on December 2, 2020 an initial delivery of approximately 11.7 million shares of our common stock, which is approximately 80% of the total number of shares that could be repurchased under the ASR Agreements if the final purchase price per share equaled the closing price of our common stock on November 30, 2020. These repurchased shares became treasury shares and were recorded as a $165.7 million reduction to stockholders’ equity. The remaining $34.3 million of the Prepayment Amount was recorded as a reduction to stockholders’ equity as an unsettled forward contract indexed to our common stock. The total number of shares received under the ASR Agreements, after final settlement, was based on the average daily volume weighted average price of our common stock during the repurchase period, less an agreed upon discount. Final settlement of the ASR Agreements occurred in May 2021, resulting in the receipt of 1.6 million additional shares, which yielded a weighted-average share repurchase price of approximately $15.07 for the repurchase period.

On June 14, 2021, we entered into Supplemental Confirmations (each, a “June 2021 Supplemental Confirmation”) to the Master Confirmations dated November 30, 2020 (each, as supplemented by the corresponding June 2021 Supplemental Confirmation, a “June 2021 ASR Agreement”), with each of the ASR Counterparties, to purchase shares of our common stock for a total payment of $200.0 million (the “June 2021 Prepayment Amount”). Under the terms of the June 2021 ASR Agreements, on June 14, 2021, we paid the June 2021 Prepayment Amount to the ASR Counterparties and received on June 16, 2021 an initial delivery of approximately 9.1 million shares of our common stock, which is approximately 80% of the total number of shares that could be repurchased under the June 2021 ASR Agreements if the final purchase price per share equaled the closing price of our common stock on June 14, 2021. These repurchased shares became treasury shares and were recorded as a $161.2 million reduction to stockholders’ equity. The remaining $38.8 million of the June 2021 Prepayment Amount was recorded as a reduction to stockholders’ equity as an unsettled forward contract indexed to our common stock. We excluded the potential share impact of any remaining shares subject to repurchase from the computation of diluted earnings per share as these shares would be anti-dilutive as of June 30, 2021. The approximate dollar value of shares of our common stock that may yet be purchased under the 2021 Program following the June 2021 ASR Agreements was $108.4 million as of June 30, 2021.

At final settlement, depending on the final purchase price per share, the ASR Counterparties may be required to deliver additional shares of our common stock to the Company, or, under certain circumstances, we may be required to make a cash payment to each ASR Counterparty or may elect to deliver the equivalent value in shares of our common stock. The final purchase price per share under each June 2021 ASR Agreement will generally be based on the average of daily volume weighted average prices of shares of our common stock during a term set forth in the June 2021 ASR Agreements. The June 2021 ASR Agreements contain provisions customary for agreements of this type, including provisions for adjustments to the transaction terms, the circumstances generally under which the June 2021 ASR Agreements may be accelerated, extended or terminated early by the ASR Counterparties and various acknowledgments, representations and warranties made by the parties to one another. Final settlement of the June 2021 ASR Agreements is expected to be completed during the fourth quarter of 2021, although the settlement may be accelerated at the ASR Counterparties’ option.

Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

Earnings (Loss) Per Share

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

8. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted-average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of restricted stock unit awards and warrants calculated under the treasury stock method.

The calculations of earnings (loss) per share are as follows:

	Three Months Ended June 30,					Six Months Ended June 30,
(In thousands, except per share amounts)	2021		2020			2021		2020
Basic earnings (loss) per Common Share:
Income (loss) from continuing operations, net of tax	$	21,905	$	(21,579	)	$	30,498	$	(53,964	)
Income from discontinued operations, net of tax		21		13,974			485		26,005
Net income (loss)	$	21,926	$	(7,605	)	$	30,983	$	(27,959	)

Weighted-average common shares outstanding		136,647		162,682			138,409		162,571

Basic earnings (loss) from continuing operations per Common Share	$	0.16	$	(0.13	)	$	0.22	$	(0.33	)
Basic earnings from discontinued operations per Common Share		0.00		0.08			0.00		0.16
Net earnings (loss) per Common Share	$	0.16	$	(0.05	)	$	0.22	$	(0.17	)

Diluted earnings (loss) per Common Share:
Income (loss) from continuing operations, net of tax	$	21,905	$	(21,579	)	$	30,498	$	(53,964	)
Income from discontinued operations, net of tax		21		13,974			485		26,005
Net income (loss)	$	21,926	$	(7,605	)	$	30,983	$	(27,959	)

Weighted-average common shares outstanding		136,647		162,682			138,409		162,571
Plus: Dilutive effect of restricted stock unit awards and warrants		8,624		0			8,839		0
Weighted-average common shares outstanding assuming dilution		145,271		162,682			147,248		162,571

Diluted earnings (loss) from continuing operations per Common Share	$	0.15	$	(0.13	)	$	0.21	$	(0.33	)
Diluted earnings from discontinued operations per Common Share		0.00		0.08			0.00		0.16
Net earnings (loss) per Common Share	$	0.15	$	(0.05	)	$	0.21	$	(0.17	)

Due to the net loss for the three and six months ended June 30, 2020, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share, since the inclusion of any stock equivalents would be anti-dilutive.

The following restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such restricted stock unit awards and warrants in the computation would be anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Shares subject to anti-dilutive restricted stock unit awards and warrants excluded from calculation		1,502		50,988		1,501		49,304

Goodwill and Intangible Assets

6 Months Ended

Jun. 30, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

9. Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following:

	June 30, 2021							December 31, 2020
	Gross							Gross
	Carrying		Accumulated			Intangible		Carrying		Accumulated			Intangible
(In thousands)	Amount		Amortization			Assets, Net		Amount		Amortization			Assets, Net
Intangibles subject to amortization:
Proprietary technology	$	535,156	$	(479,059	)	$	56,097	$	535,092	$	(465,292	)	$	69,800
Customer contracts and relationships		674,347		(521,186	)		153,161		674,336		(509,534	)		164,802
Total	$	1,209,503	$	(1,000,245	)	$	209,258	$	1,209,428	$	(974,826	)	$	234,602

Intangibles not subject to amortization:
Registered trademarks						$	52,000						$	52,000
Goodwill							974,834							974,729
Total						$	1,026,834						$	1,026,729

Changes in the carrying amounts of goodwill by reportable segment for the six months ended June 30, 2021 were as follows:

(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Total
Balance as of December 31, 2020		735,502		239,227		974,729
Foreign exchange translation		105		0		105
Balance as of June 30, 2021	$	735,607	$	239,227	$	974,834

There were no accumulated impairment losses associated with goodwill as of June 30, 2021 and December 31, 2020.

Debt

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Debt

10. Debt

Debt outstanding, excluding lease obligations, consists of the following:

	June 30, 2021							December 31, 2020
(In thousands)	Principal Balance		Unamortized Discount and Debt Issuance Costs			Net Carrying Amount		Principal Balance		Unamortized Discount and Debt Issuance Costs			Net Carrying Amount
0.875% Convertible Senior Notes ⁽¹⁾	$	167,853	$	(6,099	)	$	173,952	$	167,853	$	(3,166	)	$	171,019
Senior Secured Credit Facility		250,000		2,640			247,360		0		3,432			(3,432	)
Total debt	$	417,853	$	(3,459	)	$	421,312	$	167,853	$	266		$	167,587

(1)	Principal balance is $207,911 thousand; $167,853 thousand is recognized in debt and $40,058 thousand is recognized in additional paid-in capital.

Interest expense consists of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Interest expense	$	1,079	$	4,599	$	2,367	$	9,548
Amortization of discounts and debt issuance costs		1,870		5,715		3,725		11,431
Total interest expense	$	2,949	$	10,314	$	6,092	$	20,979

Interest expense related to the 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes (which matured and were repaid in full on July 1, 2020), included in the table above, consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Coupon interest	$	455	$	1,555	$	910	$	3,110
Amortization of discounts and debt issuance costs		1,474		5,288		2,933		10,576
Total interest expense related to the convertible notes	$	1,929	$	6,843	$	3,843	$	13,686

Allscripts Senior Secured Credit Facility

On February 15, 2018, Allscripts and Allscripts Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the “Second Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent. The Second Amended Credit Agreement provides for a $400 million senior secured term loan (the “Term Loan”) and a $900 million senior secured revolving facility (the “Revolving Facility”), each with a five-year term. The Term Loan was repayable in quarterly installments, which began on June 30, 2018. We repaid the Term Loan in full on December 31, 2020. A total of up to $50 million of the Revolving Facility is available for the issuance of letters of credit, up to $10 million of the Revolving Facility is available for swingline loans, and up to $100 million of the Revolving Facility could be borrowed under certain foreign currencies.

As of June 30, 2021, $250.0 million under the Revolving Facility and $1.0 million in letters of credit were outstanding under the Second Amended Credit Agreement.

As of June 30, 2021, the interest rate on the borrowings under the Second Amended Credit Agreement was LIBOR plus 1.50%, which totaled 1.60%. We were in compliance with all covenants under the Second Amended Credit Agreement as of June 30, 2021.

In connection with the sale of our EPSibusiness on October 15, 2020, which is further discussed in Note 5, “Business Combinations and Divestitures”, the terms of our Second Amended Credit Agreement required us to make a mandatory prepayment of our Term Loan in the amount of $19.0 million on October 29, 2020.

In connection with the sale of our CarePort business on December 31, 2020, which is further discussed in Note 5, “Business Combinations and Divestitures”, the terms of our Second Amended Credit Agreement required us to make a mandatory prepayment of our Term Loan in the amount of $161.0 million on December 31, 2020.

On August 7, 2019, we entered into a First Amendment to the Second Amended Credit Agreement in order to remain compliant with the covenants of our Second Amended Credit Agreement. The First Amendment provided the financial flexibility to settle the U.S. Department of Justice’s investigations as discussed in Note 14, “Contingencies”, while maintaining our compliance with the covenants of our Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended.

On July 20, 2020, we entered into a Second Amendment to the Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended. In connection with this amendment, we incurred fees and other costs totaling $1.4 million, of which a majority was capitalized.

As of June 30, 2021, we had $649.0 million available borrowing capacity, net of outstanding letters of credit, under the Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of the Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings or if we are unable to maintain compliance with applicable covenants.

0.875% Convertible Senior Notes

The issuance in December 2019 of the combined $218.0 million aggregate principal amount of the 0.875% Convertible Senior Notes resulted in $0.7 million in debt issuance costs, which were paid in January 2020. We have separately recorded liability and equity components of the 0.875% Convertible Senior Notes, including any discounts and issuance costs, by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This allocation was completed by first estimating an interest rate at the time of issuance for similar notes that do not include an embedded conversion option. The semi-annual interest rate of 1.95% was used to compute the initial fair value of the liability component, which totaled $177.9 million at the time of issuance. The excess of the initial proceeds received from the 0.875% Convertible Senior Notes and the $177.9 million liability component was allocated to the equity component, which totaled $40.1 million at the time of issuance before deducting any paid capped call fees. The equity component of $40.1 million, the $17.2 million in paid capped call fees and an allocation of $1.1 million in combined discounts and issuance costs were recorded in Additional paid-in capital within the consolidated balance sheets in December 2019. These were recorded as a discount that will be accreted into interest expense through January 1, 2027 using the interest method. In June 2020, we paid $7.7 million to repurchase $10.1 million of the aggregate principal amount of the 0.875% Convertible Senior Notes, which resulted in a $0.5 million gain. In connection with the repurchase, the capped call transaction was partially terminated, and we received $0.3 million, which resulted in a recognition of $0.8 million in equity to offset the capped call fees and a $0.5 million loss. The remaining principal amount of the 0.875% Convertible Senior Notes at June 30, 2021 totaled $207.9 million. The carrying value of the combined equity component, net of capped call fees, issuance costs and accretion, at June 30, 2021 totaled $13.6 million.

Future Debt Payments

The following table summarizes future debt payment obligations as of June 30, 2021:


(In thousands)	Total		Remainder of 2021		2022		2023		2024		2025		Thereafter
0.875% Convertible Senior Notes ⁽¹⁾	$	207,911	$	0	$	0	$	0	$	0	$	0	$	207,911
Revolving Facility ⁽²⁾		250,000		0		0		250,000		0		0		0
Total debt	$	457,911	$	0	$	0	$	250,000	$	0	$	0	$	207,911

(1)	Amount represents face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portion.

(2)	Assumes no additional borrowings after June 30, 2021, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

Income Taxes

6 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

11. Income Taxes

We account for income taxes under FASB Accounting Standards Codification 740, “Income Taxes” (“ASC 740”). We calculate the quarterly tax provision consistent with the guidance provided by ASC 740, whereby we forecast the estimated annual effective tax rate and then apply that rate to the year-to-date pre-tax book (loss) income. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective rate, including factors such as the valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, or changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. There is no tax benefit recognized on certain of the net operating losses incurred due to insufficient evidence supporting the Company’s ability to use these losses in the future. The effective tax rates were as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands, except effective tax rate)	2021			2020			2021			2020
Income (loss) from continuing operations before income taxes	$	24,097		$	(19,570	)	$	35,353		$	(56,489	)
Income tax (provision) benefit	$	(2,192	)	$	(2,009	)	$	(4,855	)	$	2,525
Effective tax rate		9.1	%		(10.3	%)		13.7	%		4.5	%

Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate primarily due to permanent differences, income attributable to foreign jurisdictions taxed at different rates, state taxes, tax credits and certain discrete items including a windfall benefit of $4.6 million for the six months ended June 30, 2021 and a shortfall expense of $6.9 million for the six months ended June 30, 2020. Our effective tax rate for the three and six months ended June 30, 2021, compared with the prior year comparable periods, differs primarily due to the fact that the permanent items, credits and the impact of foreign earnings had more impact on the pre-tax income of $24.1 million and $35.4 million in the three and six months ended June 30, 2021, respectively, compared to the impact of these items on a pre-tax loss of $19.6 million and $56.5 million for the three and six months ended June 30, 2020, respectively.

In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). During the six months ended June 30, 2021, we released valuation allowances of $0.1 million related to U.S. and foreign net operating loss carryforwards.

Our unrecognized income tax benefits were $30.1 million and $28.9 million as of June 30, 2021 and December 31, 2020, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted considering changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations and changes in tax law.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Derivative Financial Instruments

6 Months Ended

Jun. 30, 2021

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

12. Derivative Financial Instruments

The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates:

	December 31, 2020
	Asset Derivatives
(In thousands)	Balance Sheet Location	Fair Value
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts	Prepaid expenses and other current assets	$	1,509
Total derivatives		$	1,509

Foreign Exchange Contracts

We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a percentage of forecasted monthly INR expenses over time. As of June 30, 2021, we had no forward contracts outstanding. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges.

The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss:

	Amount of Gain (Loss) Recognized in OCI						Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended June 30, 2021			Six Months Ended June 30, 2021		Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended June 30, 2021		Six Months Ended June 30, 2021
Foreign exchange contracts	$	(54	)	$	121	Cost of Revenue	$	290	$	611
						Selling, general and administrative expenses		167		351
						Research and development	$	317	$	668

	Amount of Gain (Loss) Recognized in OCI					Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended June 30, 2020		Six Months Ended June 30, 2020		Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended June 30, 2020			Six Months Ended June 30, 2020
Foreign exchange contracts	$	991	$	518	Cost of Revenue	$	(36	)	$	(36	)
					Selling, general and administrative expenses		(18	)		(18	)
					Research and development	$	(38	)	$	(38	)

Accumulated Other Comprehensive Loss

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Accumulated Other Comprehensive Loss

13. Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss

Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax.

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains (Losses) on Foreign Exchange Contracts			Total
Balance as of December 31, 2020⁽¹⁾	$	(2,957	)	$	1,119		$	(1,838	)
Other comprehensive income (loss) before reclassifications		520			90			610
Net (gains) losses reclassified from accumulated other comprehensive loss		0			(1,209	)		(1,209	)
Net other comprehensive income (loss)		520			(1,119	)		(599	)
Balance as of June 30, 2021	$	(2,437	)	$	0		$	(2,437	)

(1)	Net of taxes of $390 thousand for unrealized net gains on foreign exchange contract derivatives.

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains (Losses) on Foreign Exchange Contracts		Total
Balance as of December 31, 2019⁽¹⁾	$	(4,392	)	$	0	$	(4,392	)
Other comprehensive (loss) income before reclassifications		(1,594	)		384		(1,210	)
Net losses (gains) reclassified from accumulated other comprehensive loss		0			69		69
Net other comprehensive income (loss)		(1,594	)		453		(1,141	)
Balance as of June 30, 2020⁽²⁾	$	(5,986	)	$	453	$	(5,533	)

(1)	Net of taxes of $149 thousand arising from the revaluation of tax effects included in AOCI.

(2)	Net of taxes of $158 thousand for unrealized net gains on foreign exchange contract derivatives.

Income Tax Effects Related to Components of Other Comprehensive Income (Loss)

The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”):

	Three Months Ended June 30,
	2021								2020
(In thousands)	Before-Tax Amount			Tax Effect		Net Amount			Before-Tax Amount		Tax Effect			Net Amount
Foreign currency translation adjustments	$	421		$	0	$	421		$	918	$	0		$	918
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net (losses) gains arising during the period		(54	)		14		(40	)		991		(256	)		735
Net (gains) losses reclassified into income		(774	)		200		(574	)		93		(24	)		69
Net change in unrealized (losses) gains on foreign exchange contracts		(828	)		214		(614	)		1,084		(280	)		804
Other comprehensive (loss) income	$	(407	)	$	214	$	(193	)	$	2,002	$	(280	)	$	1,722

	Six Months Ended June 30,
	2021									2020
(In thousands)	Before-Tax Amount			Tax Effect			Net Amount			Before-Tax Amount			Tax Effect			Net Amount
Foreign currency translation adjustments	$	520		$	0		$	520		$	(1,594	)	$	0		$	(1,594	)
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net gains (losses) arising during the period		121			(31	)		90			518			(134	)		384
Net (gains) losses reclassified into income		(1,630	)		421			(1,209	)		93			(24	)		69
Net change in unrealized (losses) gains on foreign exchange contracts		(1,509	)		390			(1,119	)		611			(158	)		453
Other comprehensive (loss) income	$	(989	)	$	390		$	(599	)	$	(983	)	$	(158	)	$	(1,141	)

Contingencies

6 Months Ended

Jun. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Contingencies

14. Contingencies

In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves, as appropriate, in these matters.

No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made.

The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results.

The Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation (“McKesson”) on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York. The CID requests documents and information related to the certification McKesson obtained for Horizon Clinicals in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. In August 2018, McKesson received an additional CID seeking similar information for Paragon. McKesson has agreed, with respect to the CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition.

Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. Between April 2018 and June 2019, Practice Fusion received from the U.S. Department of Justice (the “DOJ”) seven additional requests for documents and information through four additional CIDs and three Health Insurance Portability and Accountability Act (“HIPAA”) subpoenas. The document and information requests received by Practice Fusion related to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program and Practice Fusion’s compliance with the Anti-Kickback Statute (“AKS”) and HIPAA as it relates to certain business practices engaged in by Practice Fusion. In March 2019, Practice Fusion received a grand jury subpoena in connection with a criminal investigation related to Practice Fusion’s compliance with the AKS. On August 6, 2019, Practice Fusion reached an agreement in principle with the DOJ to resolve all of the DOJ’s outstanding civil and criminal investigations, including the investigation by the U.S. Attorney’s Office for the District of Vermont, and we announced that on January 27, 2020, Practice Fusion entered into a deferred prosecution agreement and various civil settlement agreements, including with the Medicaid programs for each U.S. state, the District of Columbia and Puerto Rico (collectively, the “Settlement Agreements”) resolving the investigations conducted by the DOJ and the U.S. Attorney’s Office. The Settlement Agreements required Practice Fusion to, among other matters, pay a criminal fine of $25.3 million, a forfeiture payment of $959,700 and a civil settlement of $118.6 million, which includes $5.2 million designated for the state Medicaid program expenditures, all of which, as of December 31, 2020, have been paid in full.

Discontinued Operations

6 Months Ended

Jun. 30, 2021

Discontinued Operations And Disposal Groups [Abstract]

Discontinued Operations

15. Discontinued Operations

During 2020, we implemented a strategic initiative to sell two of our businesses, EPSi and CarePort. Since both businesses were part of the same strategic initiative and were sold within the same period, the combined sale of EPSi and CarePort represents a strategic shift that had a major effect on our operations and financial results. As of December 31, 2020, these businesses were reported together as discontinued operations.

On October 15, 2020, we completed the sale of our EPSi business. Prior to the sale, EPSi was part of the Unallocated category as it did not meet the requirements to be a reportable segment nor the criteria to be aggregated into our two reportable segments. On its own, the divestiture of the EPSi business did not represent a strategic shift that had a major effect on our operations and financial results. However, the combined sale of EPSi and CarePort represented a strategic shift that had a major effect on our operations and financial results. Therefore, EPSi was treated as a discontinued operation.

On December 31, 2020, we completed the sale of our CarePort business. Prior to the sale, CarePort was part of the Data, Analytics and Care Coordination reportable segment. On its own, the divestiture of the CarePort business represented a strategic shift that had a major effect on our operations and financial results.

The following table summarizes the major classes of assets and liabilities of EPSi and CarePort, as reported on the consolidated balance sheets as of June 30, 2021 and December 31, 2020:

(In thousands)	June 30, 2021		December 31, 2020
Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations:
Accrued expenses	$	2,670	$	6,669
Income tax payable		0		316,142
Total current liabilities attributable to discontinued operations	$	2,670	$	322,811

The following table summarizes the major income and expense line items of EPSi and CarePort as reported in the consolidated statements of operations for the three and six months ended June 30, 2021 and 2020. The activity during the three and six months ended June 30, 2021 relates to certain adjustments made in connection with the sale of EPSi and CarePort, primarily of which relates to net working capital adjustments that impacted the gain on the sale of the discontinued operations.

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2021			2020			2021			2020
Major income and expense line items related to EPSi and CarePort:
Revenue:
Software delivery, support and maintenance	$	363		$	32,431		$	0		$	63,913
Client services		5			4,488			0			8,366
Total revenue		368			36,919			0			72,279
Cost of revenue:
Software delivery, support and maintenance		294			3,113			(193	)		6,354
Client services		22			4,313			145			8,878
Amortization of software development and acquisition-related assets		0			2,607			0			5,124
Total cost of revenue		316			10,033			(48	)		20,356
Gross profit		52			26,886			48			51,923
Selling, general and administrative expenses		9			4,722			74			9,186
Research and development		8			2,237			(32	)		5,015
Amortization of intangible assets		0			8			0			15
Income from discontinued operations for EPSi and CarePort		35			19,919			6			37,707
Interest expense		0			(1,081	)		0			(2,639	)
Other income, net		1			0			1			0
Gain on sale of discontinued operations		0			0			647			0
Income from discontinued operations for EPSi and CarePort before income taxes ⁽¹⁾		36			18,838			654			35,068
Income tax provision		(15	)		(4,864	)		(169	)		(9,051	)
Income from discontinued operations, net of tax for EPSi and CarePort ⁽²⁾	$	21		$	13,974		$	485		$	26,017

(1) Income from discontinued operations for EPSi and CarePort does not agree to the consolidated statements of operations for the six months ended June 30, 2020, due to residual amounts related to Netsmart (as defined below). Refer to Note 17, “Supplemental Disclosures” for additional information.

(2) Income from discontinued operations, net of tax for EPSi and CarePort does not agree to the consolidated statements of operations for the six months ended June 30, 2020 due to residual amounts related to Netsmart (as defined below). Refer to Note 17, Supplemental Disclosures” for additional information.

Business Segments

6 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Business Segments

16. Business Segments

We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services, such as outsourcing, private cloud hosting and revenue cycle management.

As of June 30, 2021, we had two operating segments. The operating segments are equivalent to the reportable segments. The Core Clinical and Financial Solutions segment derives its revenue from the sale of software applications for patient engagement, integrated clinical and financial management solutions, which primarily include EHR-related software, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting and revenue cycle management. The Data, Analytics and Care Coordination segment derives its revenue from the sale of practice reimbursement and payer and life sciences solutions, which are mainly targeted at physician practices, payers, life sciences companies and other key healthcare stakeholders. These solutions enable clients to transition, analyze, coordinate care and improve the quality, efficiency and value of healthcare delivery across the entire care community. The “Unallocated Amounts” category consists of transfer pricing revenues and as of January 1, 2021 also includes certain corporate-related expenses.

Our chief operating decision maker uses segment revenues, gross profit and income (loss) from operations as measures of performance and to make decisions about the allocation of resources. We do not track our assets by segment.

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2021			2020			2021			2020
Revenue:
Core Clinical and Financial Solutions	$	310,148		$	311,099		$	619,313		$	631,431
Data, Analytics and Care Coordination		67,860			60,498			131,425			123,929
Unallocated Amounts		(4,294	)		(2,293	)		(8,672	)		(4,692	)
Total revenue	$	373,714		$	369,304		$	742,066		$	750,668

Gross profit:
Core Clinical and Financial Solutions	$	118,787		$	108,522		$	238,749		$	208,956
Data, Analytics and Care Coordination		32,966			29,076			63,049			60,578
Unallocated Amounts		0			0			0			0
Total gross profit	$	151,753		$	137,598		$	301,798		$	269,534

Income (loss) from operations:
Core Clinical and Financial Solutions	$	11,947		$	(15,834	)	$	29,552		$	(36,546	)
Data, Analytics and Care Coordination		2,875			(8,831	)		3,257			(15,095	)
Unallocated Amounts		(4,447	)		0			(9,094	)		0
Total income (loss) from operations	$	10,375		$	(24,665	)	$	23,715		$	(51,641	)

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Supplemental Disclosures

6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Supplemental Disclosures

17. Supplemental Disclosures

Supplemental Consolidated Statements of Cash Flows Information

The majority of the restricted cash balance as of June 30, 2021 represents lease deposits. The majority of the restricted cash balance as of June 30, 2020 represents lease deposits and an escrow account established as part of the acquisition of Netsmart LLC (“Netsmart”) in 2016, to be used by Netsmart to facilitate the integration of Allscripts’ former Homecare^TM business.

	June 30,
(In thousands)	2021		2020
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	229,254	$	199,004
Restricted cash		2,129		6,194
Total cash, cash equivalents and restricted cash	$	231,383	$	205,198

	Six Months Ended June 30,
(In thousands)	2021		2020
Supplemental non-cash information:
Issuance of treasury stock to commercial partner	$	534	$	752

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and six months ended June 30, 2021 and 2020 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates.
Change in Presentation	Change in Presentation Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported consolidated prior period financial results.
Recently Adopted Accounting Pronouncements	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2019-12, “Income Taxes (Topic 740)” (“ASU 2019-12”), which is part of the FASB’s overall simplification initiative to reduce the costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. ASU 2019-12 simplifies accounting guidance for intraperiod allocations, deferred tax liabilities, year-to-date losses in interim periods, franchise taxes, step-up in tax basis of goodwill, separate entity financial statements and interim recognition of tax laws or rate changes. ASU 2019-12 is effective for public business entities for annual reporting periods beginning after December 15, 2020. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have a significant impact on our consolidated financial statements.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In August 2020, the FASB issued Accounting Standards Update No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The amendments in ASU 2020-06 simplify the accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. We are currently evaluating the impact of this accounting guidance. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.
Revenue Recognition	Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2021

Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients

The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the table below:

(In thousands)	Three Months Ended March 31, 2021		Three Months Ended June 30, 2021
Revenue related to deferred revenue balance at beginning of period	$	137,848	$	151,857
Revenue related to new performance obligations satisfied during the period		173,316		158,910
Revenue recognized under "right-to-invoice" expedient		56,811		62,422
Reimbursed travel expenses, shipping and other revenue		377		525
Total revenue	$	368,352	$	373,714

(In thousands)	Three Months Ended March 31, 2020		Three Months Ended June 30, 2020
Revenue related to deferred revenue balance at beginning of period	$	105,366	$	119,545
Revenue related to new performance obligations satisfied during the period		216,580		195,308
Revenue recognized under "right-to-invoice" expedient		58,059		54,082
Reimbursed travel expenses, shipping and other revenue		1,359		369
Total revenue	$	381,364	$	369,304

Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments

The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Revenue:
Recurring revenue	$	303,644	$	303,196	$	599,292	$	613,177
Non-recurring revenue		70,070		66,108		142,774		137,491
Total revenue	$	373,714	$	369,304	$	742,066	$	750,668

Summary of Changes in Estimate of Credit Losses for Contract Assets

Changes in the estimate of credit losses for contract assets are presented in the table below.

(In thousands)	Total
Balance at December 31, 2020	$	5,341
Current period provision		0
Balance at June 30, 2021	$	5,341
Less: Contract assets, short-term		1,068
Total contract assets, long-term	$	4,273

Revenue by Segment [Member]

Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments

	Three Months Ended June 30, 2021
(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Unallocated Amounts			Total
Software delivery, support and maintenance	$	158,754	$	65,150	$	(4,294	)	$	219,610
Client services		151,394		2,710		0			154,104
Total revenue	$	310,148	$	67,860	$	(4,294	)	$	373,714

	Three Months Ended June 30, 2020
(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Unallocated Amounts			Total
Software delivery, support and maintenance	$	167,220	$	58,664	$	(2,293	)	$	223,591
Client services		143,879		1,834		0			145,713
Total revenue	$	311,099	$	60,498	$	(2,293	)	$	369,304

	Six Months Ended June 30, 2021
(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Unallocated Amounts			Total
Software delivery, support and maintenance	$	323,964	$	127,009	$	(8,672	)	$	442,301
Client services		295,349		4,416		0			299,765
Total revenue	$	619,313	$	131,425	$	(8,672	)	$	742,066

	Six Months Ended June 30, 2020
(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Unallocated Amounts			Total
Software delivery, support and maintenance	$	341,301	$	119,122	$	(4,692	)	$	455,731
Client services		290,130		4,807		0			294,937
Total revenue	$	631,431	$	123,929	$	(4,692	)	$	750,668

Accounts Receivables (Tables)

6 Months Ended

Jun. 30, 2021

Trade Accounts Receivable [Member]

Accounts Notes And Loans Receivable [Line Items]

Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable

Changes in the estimate of credit losses for trade accounts receivable are presented in the tables below.

(In thousands)	Total
Balance at December 31, 2020	$	31,596
Current period provision		1,655
Write-offs		(1,721	)
Recoveries		461
Balance at June 30, 2021	$	31,991

Leases (Tables)

6 Months Ended

Jun. 30, 2021

Lessee Disclosure [Abstract]

Summary of Operating Costs Associated with Leased Assets

Operating costs associated with leased assets are as follows:

(In thousands)	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Operating lease cost ⁽¹⁾	$	5,636		$	6,261		$	11,697		$	13,014
Less: Sublease income		(74	)		(166	)		(157	)		(769	)
Total operating lease costs	$	5,562		$	6,095		$	11,540		$	12,245

(1)	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations.

Supplemental Cash Flow Information for Operating Leases

Supplemental cash flow information for operating leases is as follows:

(In thousands)	Six Months Ended June 30,
	2021		2020
Operating cash flows from operating leases	$	10,083	$	13,953
Right-of-use assets obtained in exchange for operating lease obligations	$	0	$	21,963

Summary of Balance Sheet Location and Balances for Operating Leases

The balance sheet location and balances for operating leases are as follows:

(In thousands, except lease term and discount rate)	June 30, 2021			December 31, 2020
Right-of-use assets - operating leases	$	75,052		$	96,601
Current operating lease liabilities	$	19,662		$	22,264
Long-term operating lease liabilities	$	71,597		$	93,463
Weighted average remaining lease term (in years)		5			6
Weighted average discount rate		3.3	%		3.6	%

Summary of Future Maturities of Lease and Non-Lease Components

	June 30, 2021
(In thousands)	Operating Leases
Remainder of 2021	$	11,590
2022		21,348
2023		19,547
2024		14,114
2025		12,764
Thereafter		20,104
Total lease liabilities		99,467
Less: Amount representing interest		(8,208	)
Less: Short-term lease liabilities		(19,662	)
Total long-term lease liabilities	$	71,597

Fair Value Measurements and Long-term Investments (Tables)

6 Months Ended

Jun. 30, 2021

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:

	Balance Sheet	June 30, 2021								December 31, 2020
(In thousands)	Classifications	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Foreign exchange derivative assets	Prepaid expenses and other current assets	$	0	$	0	$	0	$	0	$	0	$	1,509	$	0	$	1,509
Total assets		$	0	$	0	$	0	$	0	$	0	$	1,509	$	0	$	1,509

Contingent consideration - current	Accrued expenses	$	0	$	0	$	153	$	153	$	0	$	0	$	1,011	$	1,011
Total liabilities		$	0	$	0	$	153	$	153	$	0	$	0	$	1,011	$	1,011

Summary of Changes in Liability Measured at Fair Value on Recurring Basis

The changes in our Level 3 liability measured at fair value on a recurring basis at June 30, 2021 is summarized as follows:

(In thousands)	Contingent Consideration
Balance at December 31, 2020	$	1,011
Payments		(858	)
Balance at June 30, 2021	$	153

Summary of Quantitative Information About Fair Value Measurements

The following table summarizes the quantitative information about our Level 3 fair value measurements at June 30, 2021:

June 30, 2021

(In thousands, except the discount rate)

Fair Value

Valuation Technique

Significant Unobservable Inputs

Ranges of Inputs

Weighted Average ⁽¹⁾

Financial instruments:

Contingent consideration

153

Probability Weighted Discounted cash flow

Discount rate

5.3% to 5.5%

5.4

Registry members

0 to 1,551

776

Patient data volume

0 to 52,845

26,422

Projected year of payment

2021

Total financial instruments

153

(1)	The weighted average is calculated based upon the absolute fair value of the instruments.

Long-Term Equity and Cost Method Investments [Member]

Summary of Long-term Equity Investments Included in Other Assets

The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets:

	Number of Investees		Original		Carrying Value at
(In thousands, except for number of investees)	at June 30, 2021		Cost		June 30, 2021		December 31, 2020
Equity method investments ⁽¹⁾		3	$	7,099	$	10,438	$	10,744
Cost less impairment		8		37,568		37,976		25,059
Total long-term equity investments		11	$	44,667	$	48,414	$	35,803

(1)	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Share-Based Compensation Expense

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Cost of revenue:
Software delivery, support and maintenance	$	311	$	343	$	807	$	918
Client services		967		808		2,346		1,899
Total cost of revenue		1,278		1,151		3,153		2,817
Selling, general and administrative expenses		7,551		5,081		15,594		12,123
Research and development		1,554		1,428		3,467		3,823
Total stock-based compensation expense	$	10,383	$	7,660	$	22,214	$	18,763

Share-Based Awards Granted

We granted stock-based awards as follows:

	Three Months Ended June 30, 2021				Six Months Ended June 30, 2021
			Weighted-Average				Weighted-Average
			Grant Date				Grant Date
(In thousands, except per share amounts)	Shares		Fair Value		Shares		Fair Value
Service-based restricted stock units		1,963	$	15.41		2,445	$	15.36
Performance-based restricted stock units with a service condition		0	$	0.00		235	$	15.16
Market-based restricted stock units with a service condition		0	$	0.00		235	$	17.19
		1,963	$	15.41		2,915	$	15.49

Earnings (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Calculations of Earnings (Loss) Per Share

The calculations of earnings (loss) per share are as follows:

	Three Months Ended June 30,					Six Months Ended June 30,
(In thousands, except per share amounts)	2021		2020			2021		2020
Basic earnings (loss) per Common Share:
Income (loss) from continuing operations, net of tax	$	21,905	$	(21,579	)	$	30,498	$	(53,964	)
Income from discontinued operations, net of tax		21		13,974			485		26,005
Net income (loss)	$	21,926	$	(7,605	)	$	30,983	$	(27,959	)

Weighted-average common shares outstanding		136,647		162,682			138,409		162,571

Basic earnings (loss) from continuing operations per Common Share	$	0.16	$	(0.13	)	$	0.22	$	(0.33	)
Basic earnings from discontinued operations per Common Share		0.00		0.08			0.00		0.16
Net earnings (loss) per Common Share	$	0.16	$	(0.05	)	$	0.22	$	(0.17	)

Diluted earnings (loss) per Common Share:
Income (loss) from continuing operations, net of tax	$	21,905	$	(21,579	)	$	30,498	$	(53,964	)
Income from discontinued operations, net of tax		21		13,974			485		26,005
Net income (loss)	$	21,926	$	(7,605	)	$	30,983	$	(27,959	)

Weighted-average common shares outstanding		136,647		162,682			138,409		162,571
Plus: Dilutive effect of restricted stock unit awards and warrants		8,624		0			8,839		0
Weighted-average common shares outstanding assuming dilution		145,271		162,682			147,248		162,571

Diluted earnings (loss) from continuing operations per Common Share	$	0.15	$	(0.13	)	$	0.21	$	(0.33	)
Diluted earnings from discontinued operations per Common Share		0.00		0.08			0.00		0.16
Net earnings (loss) per Common Share	$	0.15	$	(0.05	)	$	0.21	$	(0.17	)

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Shares subject to anti-dilutive restricted stock unit awards and warrants excluded from calculation		1,502		50,988		1,501		49,304

Goodwill and Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following:

	June 30, 2021							December 31, 2020
	Gross							Gross
	Carrying		Accumulated			Intangible		Carrying		Accumulated			Intangible
(In thousands)	Amount		Amortization			Assets, Net		Amount		Amortization			Assets, Net
Intangibles subject to amortization:
Proprietary technology	$	535,156	$	(479,059	)	$	56,097	$	535,092	$	(465,292	)	$	69,800
Customer contracts and relationships		674,347		(521,186	)		153,161		674,336		(509,534	)		164,802
Total	$	1,209,503	$	(1,000,245	)	$	209,258	$	1,209,428	$	(974,826	)	$	234,602

Intangibles not subject to amortization:
Registered trademarks						$	52,000						$	52,000
Goodwill							974,834							974,729
Total						$	1,026,834						$	1,026,729

Changes in Carrying Amount of Goodwill

Changes in the carrying amounts of goodwill by reportable segment for the six months ended June 30, 2021 were as follows:

(In thousands)	Core Clinical and Financial Solutions		Data, Analytics and Care Coordination		Total
Balance as of December 31, 2020		735,502		239,227		974,729
Foreign exchange translation		105		0		105
Balance as of June 30, 2021	$	735,607	$	239,227	$	974,834

Debt (Tables)

6 Months Ended

Jun. 30, 2021

Debt Instrument [Line Items]

Debt Outstanding Excluding Lease Obligations

Debt outstanding, excluding lease obligations, consists of the following:

	June 30, 2021							December 31, 2020
(In thousands)	Principal Balance		Unamortized Discount and Debt Issuance Costs			Net Carrying Amount		Principal Balance		Unamortized Discount and Debt Issuance Costs			Net Carrying Amount
0.875% Convertible Senior Notes ⁽¹⁾	$	167,853	$	(6,099	)	$	173,952	$	167,853	$	(3,166	)	$	171,019
Senior Secured Credit Facility		250,000		2,640			247,360		0		3,432			(3,432	)
Total debt	$	417,853	$	(3,459	)	$	421,312	$	167,853	$	266		$	167,587

(1)	Principal balance is $207,911 thousand; $167,853 thousand is recognized in debt and $40,058 thousand is recognized in additional paid-in capital.

Interest Expense

Interest expense consists of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Interest expense	$	1,079	$	4,599	$	2,367	$	9,548
Amortization of discounts and debt issuance costs		1,870		5,715		3,725		11,431
Total interest expense	$	2,949	$	10,314	$	6,092	$	20,979

Summary of Future Debt Payment Obligations

Future Debt Payments

The following table summarizes future debt payment obligations as of June 30, 2021:


(In thousands)	Total		Remainder of 2021		2022		2023		2024		2025		Thereafter
0.875% Convertible Senior Notes ⁽¹⁾	$	207,911	$	0	$	0	$	0	$	0	$	0	$	207,911
Revolving Facility ⁽²⁾		250,000		0		0		250,000		0		0		0
Total debt	$	457,911	$	0	$	0	$	250,000	$	0	$	0	$	207,911

(1)	Amount represents face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portion.

(2)	Assumes no additional borrowings after June 30, 2021, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes [Member]

Debt Instrument [Line Items]

Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Coupon interest	$	455	$	1,555	$	910	$	3,110
Amortization of discounts and debt issuance costs		1,474		5,288		2,933		10,576
Total interest expense related to the convertible notes	$	1,929	$	6,843	$	3,843	$	13,686

Income Taxes (Tables)

6 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Effective Tax Rates

The effective tax rates were as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands, except effective tax rate)	2021			2020			2021			2020
Income (loss) from continuing operations before income taxes	$	24,097		$	(19,570	)	$	35,353		$	(56,489	)
Income tax (provision) benefit	$	(2,192	)	$	(2,009	)	$	(4,855	)	$	2,525
Effective tax rate		9.1	%		(10.3	%)		13.7	%		4.5	%

Derivative Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2021

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Fair Value and Balance Sheet Locations

The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates:

	December 31, 2020
	Asset Derivatives
(In thousands)	Balance Sheet Location	Fair Value
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts	Prepaid expenses and other current assets	$	1,509
Total derivatives		$	1,509

Derivatives Instruments Designated as Cash Flow Hedges

The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss:

	Amount of Gain (Loss) Recognized in OCI						Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended June 30, 2021			Six Months Ended June 30, 2021		Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended June 30, 2021		Six Months Ended June 30, 2021
Foreign exchange contracts	$	(54	)	$	121	Cost of Revenue	$	290	$	611
						Selling, general and administrative expenses		167		351
						Research and development	$	317	$	668

	Amount of Gain (Loss) Recognized in OCI					Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended June 30, 2020		Six Months Ended June 30, 2020		Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended June 30, 2020			Six Months Ended June 30, 2020
Foreign exchange contracts	$	991	$	518	Cost of Revenue	$	(36	)	$	(36	)
					Selling, general and administrative expenses		(18	)		(18	)
					Research and development	$	(38	)	$	(38	)

Accumulated Other Comprehensive Loss (Tables)

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Components of Accumulated Other Comprehensive Loss

Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax.

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains (Losses) on Foreign Exchange Contracts			Total
Balance as of December 31, 2020⁽¹⁾	$	(2,957	)	$	1,119		$	(1,838	)
Other comprehensive income (loss) before reclassifications		520			90			610
Net (gains) losses reclassified from accumulated other comprehensive loss		0			(1,209	)		(1,209	)
Net other comprehensive income (loss)		520			(1,119	)		(599	)
Balance as of June 30, 2021	$	(2,437	)	$	0		$	(2,437	)

(1)	Net of taxes of $390 thousand for unrealized net gains on foreign exchange contract derivatives.

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains (Losses) on Foreign Exchange Contracts		Total
Balance as of December 31, 2019⁽¹⁾	$	(4,392	)	$	0	$	(4,392	)
Other comprehensive (loss) income before reclassifications		(1,594	)		384		(1,210	)
Net losses (gains) reclassified from accumulated other comprehensive loss		0			69		69
Net other comprehensive income (loss)		(1,594	)		453		(1,141	)
Balance as of June 30, 2020⁽²⁾	$	(5,986	)	$	453	$	(5,533	)

(1)	Net of taxes of $149 thousand arising from the revaluation of tax effects included in AOCI.

(2)	Net of taxes of $158 thousand for unrealized net gains on foreign exchange contract derivatives.

Income Tax Effects Related to Components of Other Comprehensive Income (Loss)

The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”):

	Three Months Ended June 30,
	2021								2020
(In thousands)	Before-Tax Amount			Tax Effect		Net Amount			Before-Tax Amount		Tax Effect			Net Amount
Foreign currency translation adjustments	$	421		$	0	$	421		$	918	$	0		$	918
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net (losses) gains arising during the period		(54	)		14		(40	)		991		(256	)		735
Net (gains) losses reclassified into income		(774	)		200		(574	)		93		(24	)		69
Net change in unrealized (losses) gains on foreign exchange contracts		(828	)		214		(614	)		1,084		(280	)		804
Other comprehensive (loss) income	$	(407	)	$	214	$	(193	)	$	2,002	$	(280	)	$	1,722

	Six Months Ended June 30,
	2021									2020
(In thousands)	Before-Tax Amount			Tax Effect			Net Amount			Before-Tax Amount			Tax Effect			Net Amount
Foreign currency translation adjustments	$	520		$	0		$	520		$	(1,594	)	$	0		$	(1,594	)
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net gains (losses) arising during the period		121			(31	)		90			518			(134	)		384
Net (gains) losses reclassified into income		(1,630	)		421			(1,209	)		93			(24	)		69
Net change in unrealized (losses) gains on foreign exchange contracts		(1,509	)		390			(1,119	)		611			(158	)		453
Other comprehensive (loss) income	$	(989	)	$	390		$	(599	)	$	(983	)	$	(158	)	$	(1,141	)

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2021

EPSi and CarePort [Member]

Summary of Discontinued Operations in Financial Statements

The following table summarizes the major classes of assets and liabilities of EPSi and CarePort, as reported on the consolidated balance sheets as of June 30, 2021 and December 31, 2020:

(In thousands)	June 30, 2021		December 31, 2020
Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations:
Accrued expenses	$	2,670	$	6,669
Income tax payable		0		316,142
Total current liabilities attributable to discontinued operations	$	2,670	$	322,811

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2021			2020			2021			2020
Major income and expense line items related to EPSi and CarePort:
Revenue:
Software delivery, support and maintenance	$	363		$	32,431		$	0		$	63,913
Client services		5			4,488			0			8,366
Total revenue		368			36,919			0			72,279
Cost of revenue:
Software delivery, support and maintenance		294			3,113			(193	)		6,354
Client services		22			4,313			145			8,878
Amortization of software development and acquisition-related assets		0			2,607			0			5,124
Total cost of revenue		316			10,033			(48	)		20,356
Gross profit		52			26,886			48			51,923
Selling, general and administrative expenses		9			4,722			74			9,186
Research and development		8			2,237			(32	)		5,015
Amortization of intangible assets		0			8			0			15
Income from discontinued operations for EPSi and CarePort		35			19,919			6			37,707
Interest expense		0			(1,081	)		0			(2,639	)
Other income, net		1			0			1			0
Gain on sale of discontinued operations		0			0			647			0
Income from discontinued operations for EPSi and CarePort before income taxes ⁽¹⁾		36			18,838			654			35,068
Income tax provision		(15	)		(4,864	)		(169	)		(9,051	)
Income from discontinued operations, net of tax for EPSi and CarePort ⁽²⁾	$	21		$	13,974		$	485		$	26,017

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Business Segments (Tables)

6 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts

	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2021			2020			2021			2020
Revenue:
Core Clinical and Financial Solutions	$	310,148		$	311,099		$	619,313		$	631,431
Data, Analytics and Care Coordination		67,860			60,498			131,425			123,929
Unallocated Amounts		(4,294	)		(2,293	)		(8,672	)		(4,692	)
Total revenue	$	373,714		$	369,304		$	742,066		$	750,668

Gross profit:
Core Clinical and Financial Solutions	$	118,787		$	108,522		$	238,749		$	208,956
Data, Analytics and Care Coordination		32,966			29,076			63,049			60,578
Unallocated Amounts		0			0			0			0
Total gross profit	$	151,753		$	137,598		$	301,798		$	269,534

Income (loss) from operations:
Core Clinical and Financial Solutions	$	11,947		$	(15,834	)	$	29,552		$	(36,546	)
Data, Analytics and Care Coordination		2,875			(8,831	)		3,257			(15,095	)
Unallocated Amounts		(4,447	)		0			(9,094	)		0
Total income (loss) from operations	$	10,375		$	(24,665	)	$	23,715		$	(51,641	)

Supplemental Disclosures (Tables)

6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Supplemental Disclosures

	June 30,
(In thousands)	2021		2020
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	229,254	$	199,004
Restricted cash		2,129		6,194
Total cash, cash equivalents and restricted cash	$	231,383	$	205,198

	Six Months Ended June 30,
(In thousands)	2021		2020
Supplemental non-cash information:
Issuance of treasury stock to commercial partner	$	534	$	752

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - Accounting Standards Update 2019-12 [Member]	Jun. 30, 2021
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2021
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true

- Definition

Indicates (true false) whether accounting standards update was adopted.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)

+ Details

- Definition

Date accounting standards update was adopted, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)

+ Details

Revenue from Contracts with Customers - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($) Revenue_Stream	Jun. 30, 2020 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2020 USD ($)	Jan. 01, 2020 USD ($)	Dec. 31, 2019 USD ($)
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Number of primary revenue streams \| Revenue_Stream			2
Total backlog	$ 3,900,000		$ 3,900,000
Total backlog, percentage, year one	33.00%		33.00%
Total backlog, percentage after year one	67.00%		67.00%
Cumulative impact on retained earnings (accumulated deficit)	$ 1,393,474	$ 1,242,929	$ 1,393,474	$ 1,242,929	$ 1,678,658	$ 1,666,243	$ 1,241,780		$ 1,285,188
ASU 2016-13 [Member] \| Cumulative Effect Period Of Adoption Adjustment [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Cumulative impact on retained earnings (accumulated deficit)								$ (5,300)
Selling, General and Administrative Expenses [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	4,900	$ 5,800	10,700	$ 12,500
Prepaid Expenses and Other Current Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	15,500		15,500			16,800
Other Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	$ 27,200		$ 27,200			$ 27,900

Revenue from Contracts with Customers - Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue related to deferred revenue balance at beginning of period	$ 151,857	$ 137,848	$ 119,545	$ 105,366
Revenue related to new performance obligations satisfied during the period	158,910	173,316	195,308	216,580
Revenue recognized under "right-to-invoice" expedient	62,422	56,811	54,082	58,059
Reimbursed travel expenses, shipping and other revenue	525	377	369	1,359
Total revenue	$ 373,714	$ 368,352	$ 369,304	$ 381,364	$ 742,066	$ 750,668

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation Of Revenue [Line Items]
Recurring revenue	$ 303,644		$ 303,196		$ 599,292	$ 613,177
Non-recurring revenue	70,070		66,108		142,774	137,491
Total revenue	373,714	$ 368,352	369,304	$ 381,364	742,066	750,668
Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(4,294)		(2,293)		(8,672)	(4,692)
Core Clinical and Financial Solutions [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	310,148		311,099		619,313	631,431
Data Analytics and Care Coordination [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	67,860		60,498		131,425	123,929
Software delivery, Support and Maintenance [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	219,610		223,591		442,301	455,731
Software delivery, Support and Maintenance [Member] \| Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(4,294)		(2,293)		(8,672)	(4,692)
Software delivery, Support and Maintenance [Member] \| Core Clinical and Financial Solutions [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	158,754		167,220		323,964	341,301
Software delivery, Support and Maintenance [Member] \| Data Analytics and Care Coordination [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	65,150		58,664		127,009	119,122
Client services [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	154,104		145,713		299,765	294,937
Client services [Member] \| Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	0		0		0	0
Client services [Member] \| Core Clinical and Financial Solutions [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	151,394		143,879		295,349	290,130
Client services [Member] \| Data Analytics and Care Coordination [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 2,710		$ 1,834		$ 4,416	$ 4,807

Revenue from Contracts with Customers - Summary of Changes in Estimate of Credit Losses for Contract Assets (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Balance at December 31, 2020	$ 5,341
Current period provision	0
Balance at June 30, 2021	5,341
Contract assets, allowance	1,068	$ 1,068
Total contract assets, long-term	$ 4,273	$ 4,273

Accounts Receivables - Additional Information (Detail) - Trade Accounts Receivable [Member] - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jan. 01, 2020
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, allowance for credit loss	$ 31,991	$ 31,596
Accounting Standards Update 2016-13 [Member]
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, allowance for credit loss			$ 12,600

Accounts Receivables - Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable (Detail) - Trade Accounts Receivable [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($)
Accounts Notes And Loans Receivable [Line Items]
Balance at December 31, 2020	$ 31,596
Current period provision	1,655
Write-offs	(1,721)
Recoveries	461
Balance at June 30, 2021	$ 31,991

Leases - Additional Information (Detail) - Maximum [Member]	6 Months Ended
	Jun. 30, 2021
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	7 years
Operating leases, options to extend leases term	5 years
Operating leases, options to terminate leases term	1 year

Leases - Summary of Operating Costs Associated with Leased Assets (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Leases [Abstract]

Operating lease cost

^[1]

$ 5,636

$ 6,261

$ 11,697

$ 13,014

Less: Sublease income

(74)

(166)

(157)

(769)

Total operating lease costs

$ 5,562

$ 6,095

$ 11,540

$ 12,245

[1]	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations.

Leases - Supplemental Cash Flow Information for Operating Leases (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Operating cash flows from operating leases	$ 10,083	$ 13,953
Right-of-use assets obtained in exchange for operating lease obligations	$ 0	$ 21,963

Leases - Summary of Balance Sheet Location and Balances for Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Right-of-use assets - operating leases	$ 75,052	$ 96,601
Current operating lease liabilities	19,662	22,264
Long-term operating lease liabilities	$ 71,597	$ 93,463
Weighted average remaining lease term (in years)	5 years	6 years
Weighted average discount rate	3.30%	3.60%

Leases - Summary of Future Maturities of Lease and Non-Lease Components (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Operating Leases [Abstract]
Operating Leases, Remainder of 2021	$ 11,590
Operating Leases, 2022	21,348
Operating Leases, 2023	19,547
Operating Leases, 2024	14,114
Operating Leases, 2025	12,764
Operating Leases, Thereafter	20,104
Operating Leases, Total lease liabilities	99,467
Operating Leases, Less: Amount representing interest	(8,208)
Operating Leases, Less: Short-term lease liabilities	(19,662)	$ (22,264)
Operating Leases, Total long-term lease liabilities	$ 71,597	$ 93,463

Business Combinations and Divestitures - Additional Information (Detail) - USD ($)					3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Oct. 29, 2020	Oct. 15, 2020	Jul. 02, 2019	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
CarePort Purchase Agreement [Member] \| Senior Secured Term Loan [Member] \| Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt							$ 161,000,000.0
CarePort Purchase Agreement [Member] \| WellSky Corp [Member]
Business Acquisition [Line Items]
Sale of business unit	$ 1,350,000,000
Pre-tax gain (loss) on sale of business	933,900,000					$ 600,000
CarePort Purchase Agreement [Member] \| WellSky Corp [Member] \| Senior Secured Term Loan [Member] \| Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt	$ 161,000,000.0
EPSi Purchase Agreement [Member] \| Senior Secured Term Loan [Member] \| Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt		$ 19,000,000.0
EPSi Purchase Agreement [Member] \| Strata Decision Technology LLC [Member]
Business Acquisition [Line Items]
Sale of business unit			$ 365,000,000.0
Pre-tax gain (loss) on sale of business							$ 222,600,000
EPSi Purchase Agreement [Member] \| Strata Decision Technology LLC [Member] \| Senior Secured Term Loan [Member] \| Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt		$ 19,000,000.0
ACC Pinnacle and Diabetes Collaborative Registries [Member]
Business Acquisition [Line Items]
Total purchase price				$ 19,700,000
Purchase price initial payment				11,700,000
Potential milestone/earnout payments				5,000,000.0
Payments related to earnout agreement					$ 900,000
ACC Pinnacle and Diabetes Collaborative Registries [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Potential milestone/earnout payments				$ 8,000,000.0

Fair Value Measurements and Long-term Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 150,968	$ 136,264
Total assets	0	1,509
Total liabilities	153	1,011
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	1,509
Total liabilities	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	153	1,011
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	1,509
Foreign exchange derivative assets [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Foreign exchange derivative assets [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	1,509
Foreign exchange derivative assets [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	153	1,011
Contingent Consideration Current [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Contingent Consideration Current [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Contingent Consideration Current [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	$ 153	$ 1,011

Fair Value Measurements and Long-term Investments - Summary of Changes in Liability Measured at Fair Value on Recurring Basis (Detail) - Contingent Consideration [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2020	$ 1,011
Payments	(858)
Balance at June 30, 2021	$ 153

Fair Value Measurements and Long-term Investments - Summary of Quantitative Information About Fair Value Measurements (Detail) - Level 3 [Member]
$ in Thousands

6 Months Ended

Jun. 30, 2021

USD ($)

RegistryMember

PatientDataVolume

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Total financial instruments | $

$ 153

Projected year of payment

2021

Registry Members [Member] | Minimum [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Ranges of Inputs | RegistryMember

Registry Members [Member] | Maximum [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Ranges of Inputs | RegistryMember

1,551

Registry Members [Member] | Weighted Average [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Ranges of Inputs | RegistryMember

776

^[1]

Patient Data Volume [Member] | Minimum [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Ranges of Inputs | PatientDataVolume

Patient Data Volume [Member] | Maximum [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Ranges of Inputs | PatientDataVolume

52,845

Patient Data Volume [Member] | Weighted Average [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Ranges of Inputs | PatientDataVolume

26,422

^[1]

Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Total financial instruments | $

$ 153

Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member] | Minimum [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Ranges of Inputs

5.3

Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member] | Maximum [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Ranges of Inputs

5.5

Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member] | Weighted Average [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Ranges of Inputs

5.4

^[1]

[1]	The weighted average is calculated based upon the absolute fair value of the instruments.

Fair Value Measurements and Long-term Investments - Summary of Long-term Equity Investments Included in Other Assets (Detail)
$ in Thousands

6 Months Ended

Jun. 30, 2021

USD ($)

Investment

Dec. 31, 2020

USD ($)

Fair Value Disclosures [Abstract]

Equity method investments, Number of Investees | Investment

^[1]

Cost less impairments, Number of investees | Investment

Total long-term equity investments, Number of Investees | Investment

Equity method investments, Original Cost

^[1]

$ 7,099

Cost less impairment, Original Cost

37,568

Total long-term equity investments, Original Cost

44,667

Equity method investments, Carrying Value

^[1]

10,438

$ 10,744

Cost less impairment, Carrying Value

37,976

25,059

Total long-term equity investments, Carrying Value

$ 48,414

$ 35,803

[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and Long-term Investments - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Gain from sale of a third-party equity method investment			$ 16,800
Impairment of long-term investments	$ 0	$ 550	$ 0	$ 550
Third-party Cost Method Investments [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Conversion of notes into shares	475		475
Third-party Cost Method Investments [Member] \| Other Income (Loss), Net [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Gain on note conversion and revaluation of existing investment	$ 9,700		$ 9,700

Stockholders' Equity - Additional Information (Detail) - USD ($)							1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 16, 2021	Jun. 14, 2021	May 26, 2021	Dec. 02, 2020	Nov. 30, 2020	Nov. 18, 2020	May 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Class Of Stock [Line Items]
Capitalized stock-based compensation costs								$ 0	$ 0	$ 0	$ 0
Stock options granted								0	0	0	0
Share issued, exercise of options and release of stock awards										2,100,000		1,900,000
Shares settled for tax withholding										895,000	764,000
Common stock repurchased, amount										$ 108,953,000	$ 9,714,000
Common stock repurchased, shares									0
November 2020 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount						$ 300,000,000
Common stock repurchased, shares								5,600,000		5,600,000
Previous Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount											$ 9,700,000
Common stock repurchased, shares											1,500,000
May 2021 Stock Purchase Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount			$ 350,000,000
Common stock repurchased, shares								11,500,000
Accelerated Share Repurchase Agreement [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount		$ 200,000,000.0			$ 200,000,000.0
Initial delivery received	$ 9,100,000			$ 11,700,000
Percentage of expected shares repurchased		80.00%			80.00%
Reduction to shareholders equity		$ 161,200,000			$ 165,700,000
Reduction to shareholders equity as an unsettled forward contract		$ 38,800,000			$ 34,300,000
Receipt of shares as part of final settlement							1,600,000
Weighted-average share repurchase price							$ 15.07
Shares of common stock yet to be repurchased, amount								$ 108,400,000		$ 108,400,000

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 10,383	$ 7,660	$ 22,214	$ 18,763
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,278	1,151	3,153	2,817
Cost of revenue [Member] \| Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	311	343	807	918
Cost of revenue [Member] \| Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	967	808	2,346	1,899
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	7,551	5,081	15,594	12,123
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,554	$ 1,428	$ 3,467	$ 3,823

Stockholders' Equity - Stock-Based Awards Granted (Detail) - $ / shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	1,963	2,915
Weighted-Average Grant Date Fair Value, granted	$ 15.41	$ 15.49
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	1,963	2,445
Weighted-Average Grant Date Fair Value, granted	$ 15.41	$ 15.36
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	235
Weighted-Average Grant Date Fair Value, granted	$ 0.00	$ 15.16
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	235
Weighted-Average Grant Date Fair Value, granted	$ 0.00	$ 17.19

Earnings (Loss) Per Share - Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Basic earnings (loss) per Common Share:
Income (loss) from continuing operations, net of tax	$ 21,905	$ (21,579)	$ 30,498	$ (53,964)
Income from discontinued operations, net of tax	21	13,974	485	26,005
Net income (loss)	$ 21,926	$ (7,605)	$ 30,983	$ (27,959)
Weighted-average common shares outstanding	136,647	162,682	138,409	162,571
Basic earnings (loss) from continuing operations per Common Share	$ 0.16	$ (0.13)	$ 0.22	$ (0.33)
Basic earnings from discontinued operations per Common Share	0.00	0.08	0.00	0.16
Net income (loss) per share - Basic	$ 0.16	$ (0.05)	$ 0.22	$ (0.17)
Diluted earnings (loss) per Common Share:
Income (loss) from continuing operations, net of tax	$ 21,905	$ (21,579)	$ 30,498	$ (53,964)
Income from discontinued operations, net of tax	21	13,974	485	26,005
Net income (loss)	$ 21,926	$ (7,605)	$ 30,983	$ (27,959)
Weighted-average common shares outstanding	136,647	162,682	138,409	162,571
Plus: Dilutive effect of restricted stock unit awards and warrants	8,624	0	8,839	0
Weighted-average common shares outstanding assuming dilution	145,271	162,682	147,248	162,571
Diluted earnings (loss) from continuing operations per Common Share	$ 0.15	$ (0.13)	$ 0.21	$ (0.33)
Diluted earnings from discontinued operations per Common Share	0.00	0.08	0.00	0.16
Net income (loss) per share - Diluted	$ 0.15	$ (0.05)	$ 0.21	$ (0.17)

Earnings (Loss) Per Share - Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Shares subject to anti-dilutive restricted stock unit awards and warrants excluded from calculation	1,502	50,988	1,501	49,304

Goodwill and Intangible Assets - Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,209,503	$ 1,209,428
Accumulated Amortization	(1,000,245)	(974,826)
Intangible Assets, Net	209,258	234,602
Registered trademarks	52,000	52,000
Goodwill	974,834	974,729
Total	1,026,834	1,026,729
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	535,156	535,092
Accumulated Amortization	(479,059)	(465,292)
Intangible Assets, Net	56,097	69,800
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	674,347	674,336
Accumulated Amortization	(521,186)	(509,534)
Intangible Assets, Net	$ 153,161	$ 164,802

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($)
Goodwill [Line Items]
Goodwill	$ 974,729
Foreign exchange translation	105
Goodwill, net	974,834
Core Clinical and Financial Solutions [Member] \| Operating Segments [Member]
Goodwill [Line Items]
Goodwill	735,502
Foreign exchange translation	105
Goodwill, net	735,607
Data Analytics and Care Coordination [Member] \| Operating Segments [Member]
Goodwill [Line Items]
Goodwill	239,227
Foreign exchange translation	0
Goodwill, net	$ 239,227

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 0	$ 0

Debt - Debt Outstanding Excluding Lease Obligations (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Principal Balance	$ 417,853	$ 167,853
Unamortized Discount and Debt Issuance Costs	(3,459)	266
Net Carrying Amount	421,312	167,587
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	167,853	167,853
Unamortized Discount and Debt Issuance Costs	(6,099)	(3,166)
Net Carrying Amount	173,952	171,019
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	250,000	0
Unamortized Discount and Debt Issuance Costs	2,640	3,432
Net Carrying Amount	$ 247,360	$ (3,432)

Debt - Debt Outstanding Excluding Lease Obligations (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Debt recognized	$ 417,853	$ 167,853
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	207,911		$ 218,000
Debt recognized	167,853	167,853
Additional Paid-In Capital [Member] \| 0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Additional paid-in capital recognized	$ 40,058	$ 40,058	$ 40,100

Debt - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Debt - Interest Expense (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Debt Instrument [Line Items]
Total interest expense	$ 2,949	$ 10,314	$ 6,092	$ 20,979
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense	1,079	4,599	2,367	9,548
Amortization of discounts and debt issuance costs	1,870	5,715	3,725	11,431
Total interest expense	$ 2,949	$ 10,314	$ 6,092	$ 20,979

Debt - Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes (Detail) - 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Debt Instrument [Line Items]
Coupon interest	$ 455	$ 1,555	$ 910	$ 3,110
Amortization of discounts and debt issuance costs	1,474	5,288	2,933	10,576
Total interest expense related to the convertible notes	$ 1,929	$ 6,843	$ 3,843	$ 13,686

Debt - Additional Information (Detail) - USD ($)				1 Months Ended		6 Months Ended		12 Months Ended
Debt - Additional Information (Detail) - USD ($)	Oct. 29, 2020	Jul. 20, 2020	Feb. 15, 2018	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Debt instrument principal amount						$ 417,853,000		$ 167,853,000
Debt issuance costs						0	$ 758,000
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility, amount available borrowing capacity						649,000,000.0
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount						250,000,000		0
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount						167,853,000		167,853,000
Debt instrument principal amount					$ 218,000,000.0	$ 207,911,000
Debt instrument interest rate				0.875%	0.875%	0.875%	0.875%
Debt issuance costs					$ 700,000
Percentage of interest rate used to to compute the initial fair value of the liability component					1.95%
Debt instrument, initial fair value of liability component					$ 177,900,000
Debt instrument, net carrying value of equity component						$ 13,600,000
Payments for repurchase debt instrument				$ 7,700,000			$ 7,700,000
Debt instrument aggregate principal amount repurchased				10,100,000			$ 10,100,000
Gain on repurchase of debt instrument				500,000
Proceeds due to termination of capped call transaction				300,000
Reduction to capped call fees				800,000
Loss in capped call				$ 500,000
0.875% Convertible Senior Notes [Member] \| Additional Paid-In Capital [Member]
Debt Instrument [Line Items]
Debt instrument, equity component amount					40,100,000	$ 40,058,000		40,058,000
Payments of capped call fees					17,200,000
Debt discounts and issuance costs					$ 1,100,000
Letter of Credit [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance			$ 50,000,000
Swing Loans [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance			10,000,000
Foreign Currencies [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance			100,000,000
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity			$ 400,000,000
Senior secured credit facilities term, years			5 years
Line of credit facility, frequency of payments						The Term Loan was repayable in quarterly installments, which began on June 30, 2018. We repaid the Term Loan in full on December 31, 2020.
Second Amended Credit Agreement [Member] \| Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount						$ 250,000,000.0
Second Amended Credit Agreement [Member] \| Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Letters of credit outstanding						$ 1,000,000.0
Second Amended Credit Agreement [Member] \| Senior Secured Credit Facility [Member] \| United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage						1.60%
Second Amended Credit Agreement [Member] \| Senior Secured Credit Facility [Member] \| LIBOR Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread						1.50%
Second Amended Credit Agreement [Member] \| Senior Secured Term Loan [Member] \| EPSi Purchase Agreement [Member]
Debt Instrument [Line Items]
Prepayment of debt	$ 19,000,000.0
Second Amended Credit Agreement [Member] \| Senior Secured Term Loan [Member] \| CarePort Purchase Agreement [Member]
Debt Instrument [Line Items]
Prepayment of debt								$ 161,000,000.0
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity			$ 900,000,000
Senior secured credit facilities term, years			5 years
Fees and other costs, incurred		$ 1,400,000

Debt - Summary of Future Debt Payment Obligations (Detail) $ in Thousands	Jun. 30, 2021 USD ($)
Debt Instrument [Line Items]
Total	$ 457,911
Remainder of 2021	0
2022	0
2023	250,000
2024	0
2025	0
Thereafter	207,911
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total	207,911
Remainder of 2021	0
2022	0
2023	0
2024	0
2025	0
Thereafter	207,911
Revolving Facility [Member]
Debt Instrument [Line Items]
Total	250,000
Remainder of 2021	0
2022	0
2023	250,000
2024	0
2025	0
Thereafter	$ 0

Debt - Summary of Future Debt Payment Obligations (Parenthetical) (Detail)	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	0.875%	0.875%	0.875%

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Effective Tax Rates (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income (loss) from continuing operations before income taxes	$ 24,097	$ (19,570)	$ 35,353	$ (56,489)
Income tax (provision) benefit	$ (2,192)	$ (2,009)	$ (4,855)	$ 2,525
Effective tax rate	9.10%	(10.30%)	13.70%	4.50%

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Windfall benefit			$ 4,600
Shortfall expense				$ 6,900
Income (loss) from continuing operations before income taxes	$ 24,097	$ (19,570)	$ 35,353	$ (56,489)
Cumulative operating income loss period considered			3 years
Unrecognized income tax benefits	$ 30,100		$ 30,100		$ 28,900
U.S. and Foreign Net Operating Loss Carryforwards [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance			$ 100

- Definition

+ References

+ Details

Derivative Financial Instruments - Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 0	$ 1,509
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract [Member] \| Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 0	$ 1,509

Derivative Financial Instruments - Additional Information (Detail)	Jun. 30, 2021 Derivative
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts	0

Derivative Financial Instruments - Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI	$ (54)	$ 991	$ 121	$ 518
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	290	(36)	611	(36)
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	167	(18)	351	(18)
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	$ 317	$ (38)	$ 668	$ (38)

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			$ 1,666,243
Other comprehensive income (loss) before reclassifications			610	$ (1,210)
Net (gains) losses reclassified from accumulated other comprehensive loss			(1,209)	69
Total other comprehensive income (loss)	$ (193)	$ 1,722	(599)	(1,141)
Balance at the end of the period	1,393,474		1,393,474
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(2,957)	(4,392)
Other comprehensive income (loss) before reclassifications			520	(1,594)
Net (gains) losses reclassified from accumulated other comprehensive loss			0	0
Total other comprehensive income (loss)			520	(1,594)
Balance at the end of the period	(2,437)	(5,986)	(2,437)	(5,986)
Derivatives Qualifying as Cash Flow Hedges [Member] \| Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			1,119	0
Other comprehensive income (loss) before reclassifications			90	384
Net (gains) losses reclassified from accumulated other comprehensive loss			(1,209)	69
Total other comprehensive income (loss)			(1,119)	453
Balance at the end of the period	0	453	0	453
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(1,838)	(4,392)
Balance at the end of the period	$ (2,437)	$ (5,533)	$ (2,437)	$ (5,533)

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Jun. 30, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)		$ 390	$ 158
Revaluation of tax effects	$ 149

Accumulated Other Comprehensive Loss - Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 421	$ 918	$ 520	$ (1,594)
Other comprehensive income (loss) before income tax benefit	(407)	2,002	(989)	(983)
Foreign currency translation adjustments, Tax Effect	0	0	0	0
Other comprehensive income (loss), Tax effect	214	(280)	390	(158)
Foreign currency translation adjustments, Net	421	918	520	(1,594)
Other comprehensive (loss) income	(193)	1,722	(599)	(1,141)
Derivatives Qualifying as Cash Flow Hedges [Member] \| Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax, Amount	(54)	991	121	518
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	(774)	93	(1,630)	93
Derivatives qualifying as cash flow hedges, net change in unrealized (losses) gains on foreign exchange contracts, Before-Tax Amount	(828)	1,084	(1,509)	611
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	14	(256)	(31)	(134)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	200	(24)	421	(24)
Derivatives qualifying as cash flow hedges, net change in unrealized (losses) gains on foreign exchange contracts, Tax Effect	214	(280)	390	(158)
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	(40)	735	90	384
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	(574)	69	(1,209)	69
Derivatives qualifying as cash flow hedges, net change in unrealized (losses) gains on foreign exchange contracts, Net	$ (614)	$ 804	(1,119)	453
Other comprehensive (loss) income			$ (1,119)	$ 453

Contingencies - Additional Information (Detail) - Practice Fusion, Inc. [Member] - US Department of Justice and US Attorney [Member]	12 Months Ended
	Dec. 31, 2020 USD ($)
Criminal Fine [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 25,300,000
Forfeiture Payment [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	959,700
Civil Settlements [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	118,600,000
State Medicaid Program Expenditures [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 5,200,000

Discontinued Operations - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2020 Business
Discontinued Operations And Disposal Groups [Abstract]
Number of businesses sold	2

Discontinued Operations - Summary of Major Classes of Assets and Liabilities as Reported on Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations:
Total current liabilities attributable to discontinued operations	$ 2,670	$ 322,811
EPSi and CarePort [Member]
Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations:
Accrued expenses	2,670	6,669
Income tax payable	0	316,142
Total current liabilities attributable to discontinued operations	$ 2,670	$ 322,811

- Definition

Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References + Details

Discontinued Operations - Summary of Major Income and Expense Line Items Reported in Consolidated Statements of Operations (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Cost of revenue:

Gain on sale of discontinued operations

$ 0

$ 647

$ 0

Income from discontinued operations before income taxes

18,838

35,056

Income tax benefit (provision)

(15)

(4,864)

(169)

(9,051)

Income from discontinued operations, net of tax

13,974

485

26,005

EPSi and CarePort [Member]

Revenue:

Total revenue

368

36,919

72,279

Cost of revenue:

Total cost of revenue

316

10,033

(48)

20,356

Amortization of software development and acquisition-related assets

2,607

5,124

Gross profit

26,886

51,923

Selling, general and administrative expenses

4,722

9,186

Research and development

2,237

(32)

5,015

Amortization of intangible assets

Income from discontinued operations for EPSi and CarePort

19,919

37,707

Interest expense

(1,081)

(2,639)

Other income, net

Gain on sale of discontinued operations

647

Income from discontinued operations before income taxes

^[1]

18,838

654

35,068

Income tax benefit (provision)

(15)

(4,864)

(169)

(9,051)

Income from discontinued operations, net of tax

^[2]

13,974

485

26,017

Software delivery, Support and Maintenance [Member] | EPSi and CarePort [Member]

Revenue:

Total revenue

363

32,431

63,913

Cost of revenue:

Total cost of revenue

294

3,113

(193)

6,354

Client services [Member] | EPSi and CarePort [Member]

Revenue:

Total revenue

4,488

8,366

Cost of revenue:

Total cost of revenue

$ 22

$ 4,313

$ 145

$ 8,878

[1]	Income from discontinued operations for EPSi and CarePort does not agree to the consolidated statements of operations for the six months ended June 30, 2020, due to residual amounts related to Netsmart (as defined below). Refer to Note 17, “Supplemental Disclosures” for additional information.
[2]	Income from discontinued operations, net of tax for EPSi and CarePort does not agree to the consolidated statements of operations for the six months ended June 30, 2020 due to residual amounts related to Netsmart (as defined below). Refer to Note 17, Supplemental Disclosures” for additional information.

Business Segments - Additional Information (Detail)	6 Months Ended
Business Segments - Additional Information (Detail)	Jun. 30, 2021 Segment
Segment Reporting [Abstract]
Number of operating segments	2

Business Segments - Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting Information [Line Items]
Revenue	$ 373,714	$ 368,352	$ 369,304	$ 381,364	$ 742,066	$ 750,668
Gross profit	151,753		137,598		301,798	269,534
Income (loss) from operations:	10,375		(24,665)		23,715	(51,641)
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	(4,294)		(2,293)		(8,672)	(4,692)
Gross profit	0		0		0	0
Income (loss) from operations:	(4,447)		0		(9,094)	0
Core Clinical and Financial Solutions [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	310,148		311,099		619,313	631,431
Gross profit	118,787		108,522		238,749	208,956
Income (loss) from operations:	11,947		(15,834)		29,552	(36,546)
Data Analytics and Care Coordination [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	67,860		60,498		131,425	123,929
Gross profit	32,966		29,076		63,049	60,578
Income (loss) from operations:	$ 2,875		$ (8,831)		$ 3,257	$ (15,095)

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Supplemental Disclosures - Supplemental Disclosures (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 229,254	$ 199,004	$ 531,104
Restricted cash	2,129	6,194	$ 6,361
Total cash, cash equivalents and restricted cash	231,383	205,198
Supplemental non-cash information:
Issuance of treasury stock	$ 534	$ 752